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ABSTRACT
The prospects of nanoparticle-based drug delivery and imaging have been hindered by
insufficient understanding of the effects of nanoparticle physicochemical properties on
their in vivo disposition. Here, we present an integrative mathematical modeling and in
vivo imaging approach to quantify the relationship between nanoparticle physicochemical
properties, namely, size, surface charge, and surface chemistry, on their in vivo disposition
kinetics in healthy rats. We developed simple master equations in closed-form to
accurately represent the time-dependent concentration of nanoparticles in different
regions of the body and obtain functional relationships for predictive purpose to support
rational design of nanomedicine. We further used the observations of the in vivo study to
inform a hybrid multiscale mathematical model to predict the global biodistribution of
nanoparticles in the body and the spatiotemporal evolution of nanoparticles inside a
simulated 2D tumor. The model is supposed to be an in silico tool to predict the effect of
particle properties on biodistribution and clearance of nanoparticles and suggest design
guidelines for optimizing the distribution to the target site.

vi

Table of Contents
List of Figures .................................................................................................................................. ix
List of Supplementary Figures ........................................................................................................ x
List of Tables ................................................................................................................................... xi
List of Supplementary Tables ........................................................................................................ xii
Chapter 1 – Introduction: Modeling approaches in nanomedicine .............................................. 1
1.1.

Background ...................................................................................................................... 1

1.2.

Whole-body scale modeling............................................................................................ 2

1.3.

Tissue scale modeling...................................................................................................... 8

1.4.

Integrative multiscale modeling ................................................................................... 12

1.5.

Motivation and scope of this dissertation ................................................................... 14

Chapter 2 – Understanding drug resistance in breast cancer with mathematical oncology ...... 16
2.1.

Abstract ......................................................................................................................... 17

2.2.

Introduction ................................................................................................................... 18

2.3.

Molecular scale modeling ............................................................................................. 20

2.4.

Tissue scale modeling.................................................................................................... 23

2.5.

Conclusions .................................................................................................................... 33

Chapter 3 – Whole-body scale continuum modeling approach .................................................. 42
3.1.

Abstract ......................................................................................................................... 42

3.2.

Introduction ................................................................................................................... 44

3.3.

Methods......................................................................................................................... 47

3.4.

Results and Discussion .................................................................................................. 54

3.5.

Conclusions .................................................................................................................... 71

3.6.

Supplementary Information ......................................................................................... 74

Chapter 4 – Multiscale hybrid modeling approach .................................................................... 103
4.1.

Introduction ................................................................................................................. 103

4.2.

Methods....................................................................................................................... 106

4.2.1

Whole-body scale sub-model ............................................................................. 108

4.2.2

Tissue scale sub-model........................................................................................ 111

4.2.3

Cellular scale sub-model ..................................................................................... 118

4.3.

Results and Discussion ................................................................................................ 124
vii

4.4.

Conclusions .................................................................................................................. 127

Chapter 5 – Conclusions and Future Directions ......................................................................... 131
Appendix A: Abbreviations ......................................................................................................... 134
Appendix B: Code ........................................................................................................................ 136
References ................................................................................................................................... 137

viii

List of Figures
Figure 1-1: Schematic of a classical pharmacokinetic model. ......................................................... 4
Figure 1-2: Schematic of a physiologically based pharmacokinetic model. .................................... 6
Figure 2-1: Results of fitting the model to patient data by a regression analysis. ........................ 31
Figure 3-1: Characterization of MSNs, SPECT/CT imaging, and semi-mechanistic modeling. ....... 49
Figure 3-2: Representative SPECT/CT images (heat maps) demonstrating the spatiotemporal
evolution of whole-body biodistribution of MSNs. ....................................................................... 57
Figure 3-3: Whole-body quantitative biodistribution of MSNs. .................................................... 59
Figure 3-4: Systemic kinetics. ......................................................................................................... 62
Figure 3-5: Organ kinetics. ............................................................................................................. 66
Figure 3-6: Excretion kinetics. ........................................................................................................ 70
Figure 4-1: Model overview. ........................................................................................................ 107
Figure 4-2: Schematic of a minimal PBPK model. ........................................................................ 110
Figure 4-3: Diagrammatic representation of a section of the tissue scale modeling domain. .... 112
Figure 4-4: Snapshot of simulation domain. ................................................................................ 116
Figure 4-5: Simulation algorithm workflow of tissue scale model. ............................................. 122
Figure 4-6: Histological analysis. .................................................................................................. 123
Figure 4-7: Microvascular quantification. .................................................................................... 125
Figure 4-8: Model predictions...................................................................................................... 126
Figure 4-9: Representative tissue scale model simulations. ........................................................ 128
Figure 4-10: Quantification of spatial distribution. ..................................................................... 129

ix

List of Supplementary Figures
Figure S 1: Hydrodynamic stability of MSNs. ................................................................................. 84
Figure S 2: SPECT/CT imaging of TMS90 MSNs. ............................................................................. 85
Figure S 3: Kinetics of heart. .......................................................................................................... 86
Figure S 4: Kinetics of lungs. .......................................................................................................... 87
Figure S 5: Kinetics of liver. ............................................................................................................ 88
Figure S 6: Kinetics of spleen. ........................................................................................................ 89
Figure S 7: Kinetics of thoracic lymph nodes. ................................................................................ 90
Figure S 8: Kinetics of abdominal aorta. ........................................................................................ 91
Figure S 9: Kinetics of muscles. ...................................................................................................... 92
Figure S 10: Kinetics of brain.......................................................................................................... 94
Figure S 11: Kinetics of joints. ........................................................................................................ 96
Figure S 12: Kinetics of kidneys. ..................................................................................................... 98
Figure S 13: Functional relationships between MSN core size and area under the curve. ........... 99
Figure S 14: PEG-TMS MSNs in urine. .......................................................................................... 100

x

List of Tables
Table 1: Summary of mathematical models addressing drug resistance in cancer at different
scales. ............................................................................................................................................. 35
Table 2: List of model parameters and variables. ........................................................................ 113

xi

List of Supplementary Tables
Table S 1: Synthesis conditions of colloidally stable MSNs.......................................................... 101
Table S 2: Non-linear regression analysis. ................................................................................... 102

xii

Chapter 1 – Introduction: Modeling approaches in nanomedicine
1.1. Background
The implementation of nanotechnology in medicine promises to advance drug
delivery and diagnostic imaging1. Nanoparticle (NP)-based drug delivery and
imaging systems (nanocarriers) have the potential to package and protect cargos
that are too toxic, fragile, insoluble, or unstable to deliver as free drugs or imaging
agents. Nanocarriers can be engineered to package combined therapeutic and
diagnostic cargos (so-called theranostics) and equipped with a variety of triggering
mechanisms to release cargo on demand according to intra- or extracellular
environmental cues. Further, it is possible to engineer the nanocarrier size, shape,
and surface chemistry to enhance circulation times and direct the biodistribution of
the drug or imaging agent within the organism by ‘passive’ targeting, e.g., by the
enhanced permeability and retention (EPR) effect2, wherein NPs accumulate in
the tumor microenvironment due to its leaky vasculature characterized by ~2002000 nm diameter2 fenestrations. Finally, by surface modification of the
nanocarrier with targeting ligands that bind to receptors/antigens over-expressed
on the cells of interest, it is possible to achieve precise administration of
therapeutic cargos to specific/personalized cells or tissues via ‘active’ targeting,
while sparing collateral damage to healthy cells and potentially overcoming
multiple drug resistance3 mechanisms.
Despite the promise, clinical translation of nanomedicine is stifled by in vivo
challenges spanning across multiple scales. To reach the desired target site, NPs
must cross physiological and physical barriers, while preserving their integrity. At
1

the systemic scale, the immune system (particularly, mononuclear phagocytic
system (MPS)) acts to get rid of NPs by promoting their entrapment in liver and
spleen, thereby reducing their bioavailability. Kidneys also act to clear NPs below
a particular size (~6 nm)4, thus governing systemic kinetics of the injected dose.
Further, at the tissue scale, barriers to transport across blood vessels and diffusion
through the interstitial space can limit the availability of NPs in the biophase.
However, NP physicochemical properties play a critical role in affecting NP
interactions in vivo5-7 and are key in controlling the deliverability of cargo to the
desired biophase. To study these interactions at the microscopic scale and predict
an emergent behavior at the macroscopic scale, mathematical modeling emerges
as a critical tool. By studying particle properties in a simulated physiological
environment, suggestions for NP design guidelines and physiological interventions
can be made to optimize delivery efficacy of nanomedicine. Here, we will discuss
important modeling approaches that have been developed for NPs and are
executed at various scales to study NP behavior and effects of NP properties on
nanomedicine efficacy and safety. The various approaches have been classified
into: whole-body scale, tissue scale, and integrative multiscale.

1.2. Whole-body scale modeling
At the whole-body scale, modeling the disposition of xenobiotics primarily involves
pharmacokinetic (PK) modeling approaches, which can be classified into classical and
physiological approaches. The classical PK modeling approach deconstructs the body into
a system of compartments, where the compartments do not necessarily have an
anatomical or physiological meaning. Traditionally, the model contains a central
compartment that may be connected via rate constants to one or more peripheral
2

compartments (see Figure 1-1). The central compartment is a lumped compartment that
contains the blood pool of the body and highly perfused organs, like heart, lungs, liver,
and kidneys. Similarly, the peripheral compartment is generally formed by lumping the
poorly perfused or slowly equilibrating tissues, like fat, bones, and muscles. First-order
kinetics is typically assumed for mass transfer between compartments and for elimination
from compartments. Solutions of ordinary differential equations (ODEs) are fit to the
concentration-time data of the xenobiotic in plasma, urine, or other tissues, to obtain
estimates for numerical coefficients and relevant PK parameters like, half-life, clearance,
volume of distribution, and mean residence time. Being simplistic and empirical (datadriven), such models have great clinical relevance, e.g. dosage regimen design, but their
predictive capacity is very limited since they lack an underlying physiological and
mechanistic reference.8-10
This is where physiological PK models fill the gap. Usually referred to as
‘physiologically based pharmacokinetic (PBPK) models’, they have a similar underlying
framework as classical PK models, but have anatomically real compartments connected
via physiological blood flow rates (see Figure 1-2). The models are thus parameterized with
anatomical and physiological variables (e.g., tissue volumes, blood flow rates) and
physicochemical information of the xenobiotics (e.g., blood-tissue partition coefficients),
obtained from literature or data fitting.8,9,11 Each compartment representing a relevant
organ or tissue is sub-compartmentalized into vascular space, interstitial space, and
cellular space. Based on the physicochemical properties of the xenobiotic under
investigation, PBPK models are classified into: i) perfusion or blood flow rate-limited and
ii) diffusion or permeability-limited12. Perfusion rate-limited models assume that xenobiotic
transfer between vascular space and interstitial space of an organ is not limited by capillary
permeability, but is only governed by the blood flow rate to the organ.
3

Central compartment:

Input
ka

𝒅𝑪𝒄
= 𝒌𝒂 ∙ 𝑿 + 𝒌𝟐𝟏 ∙ 𝑪𝒑 − 𝒌𝟏𝟎 ∙ 𝑪𝒄
𝒅𝒕

k12
Central

Peripheral

Peripheral compartment:

k21
k10

𝒅𝑪𝒑
= 𝒌𝟏𝟐 ∙ 𝑪𝒄 − 𝒌𝟐𝟏 ∙ 𝑪𝒑
𝒅𝒕

Elimination

Figure 1-1: Schematic of a classical pharmacokinetic model.
A representative two-compartment model with a central compartment and a peripheral
compartment is shown. Elimination is restricted to the central compartment in this model.
Master equations for the two compartments are also shown, where 𝑘 is the rate of
absorption of NPs form the site of injection into the central compartment, 𝑘

and 𝑘

the rates of transfer of NPs between central and peripheral compartments, and 𝑘

are
is the

rate of elimination of NPs form the central compartment. All the mass transfer processes
are assumed to follow first-order kinetics and a solution of the coupled ordinary differential
equations provides the temporal evolution of NPs in the given compartments (𝐶 for central
and 𝐶 for peripheral).
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Conversely, permeability-limited models assume capillary permeability to be the limiting
factor. PBPK models serve to provide a mechanistic description of the concentration timecourse of xenobiotics in any given tissue or plasma. Like classical PK, linear kinetics is
usually assumed for mass transport across the system and coupled ODEs model the
xenobiotic concentration in tissues. Because of the framework being physiologically
meaningful, these models can help with dose extrapolation from animals to humans, or
healthy volunteers to diseased patients, based on differences in physiological
parameters.9,13 They are also valuable in predicting dose adjustments for special
populations, like pregnant women14 and pediatrics15. PBPK has also emerged as a critical
tool in addressing regulatory questions about the effect of intrinsic (e.g., organ impairment,
age, and genetics) and extrinsic factors (e.g., drug-drug interactions) on the PK and
pharmacodynamics (PD) of drugs.16
Like free drugs, the classical PK modeling of NPs requires quantification of NP
concentration (usually expressed as percent of injected dose per gram of tissue (%ID/g))
over time in plasma, urine, and other tissues. For this purpose, most commonly employed
techniques include plasma/urine radioactivity quantification17,18, whole-body radioactivity
imaging and quantification (e.g. SPECT19-24, PET25,26), fluorescent imaging26,27, MRI28,
inductively coupled plasma mass spectroscopy29, and accelerator mass spectrometry30.
The most suitable compartmental model is then fit to time course of NP concentration thus
obtained. Most in vivo studies31 report a biphasic decline in plasma (or mediastinum25, a
substitute for plasma when imaging techniques are used) concentration of NPs, following
intravenous (i.v.) injection. Thus, a two-compartment model is most commonly employed
to describe systemic NP disposition (see Figure 1-1). However, it is important to note that
the frequency of time points in the data collected can impact the nature of concentration
time course, and a biexponential decline will not always be the case.

5
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Figure 1-2: Schematic of a physiologically based pharmacokinetic model.
A representative PBPK model is shown. The various compartments are connected to the
systemic circulation compartments (arterial and venous) via physiological blood flow rates
(Qi). Liver and kidneys are the compartments responsible for clearance. Liver is shown to
have a dual blood supply (hepatic artery and portal vein). ‘Rest’ represents the tissues not
explicitly modeled and may include fat, muscle, and bones. A tumor compartment may be
included to study the deliverability of nanotherapy to the tumor tissue.
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Hence, some studies report using a one- (for monophasic decline)32 or three-compartment
(for triphasic decline) model. Thus, the selection of the type of compartmental model
depends solely on the observed nature of the concentration time course, which in turn is
dependent on the method of data collection, which gives us yet another reason for the low
predictive capability of classical PK models. Classical PK approaches have also been
employed to study nanomedicine delivery to solid tumors. Sykes et al.32 adapted a
mathematical model, developed by Schmidt and Wittrup33 for antibodies, to predict tumor
delivery efficiency of gold NPs. In this one-compartment model, representing plasma pool
of the body, a monoexponential decay function describes the clearance of NPs from blood
following i.v. injection. A tumor compartment is linked to the plasma compartment such
that monoexponential decay of NP concentration in blood acts as a forcing function to
govern influx of NPs into the tumor. As a simplification, it is assumed that NP influx into
tumor does not influence the monoexponential clearance behavior of NPs in blood. This
assumption implicitly represents absence of target mediated drug disposition (TMDD).
Once inside the tumor, permeability of tumor vessels governs the extravasation of NPs
into tumor interstitium. Following extravasation, NPs diffuse through the available volume
of tumor interstitium, bind or unbind from surface of cells, and are eventually endocytosed
and degraded by tumor cells. With all reactions assumed to follow first order kinetics, the
resulting biexponential function, which resembles Bateman function34 for oral absorption
of free drugs, describes the NP-associated, dose-normalized, fluorescence concentration
time-course (% ID/ml, percent of injected dose per ml of tumor) in the tumor compartment.
The model is then used to predict the influence of plasma clearance rate and tumor cell
binding affinity of NPs on their tumor accumulation (represented by concentration-time
area under the curve (AUC)). The model can thus be employed as an in silico platform to
test NP design configurations for their impact on tumor accumulation of NPs.

7

The application of the more mechanistic PBPK models in nanomedicine is in a very
premature stage, and most studies involve the application of PBPK models in their
canonical form11,35-37, i.e., models developed traditionally for free drugs. However,
fundamental differences between physicochemical characteristics of NPs and free drugs
demands modifications to the structure of conventional PBPK models to better fit the
purpose of modeling NP disposition kinetics. 38
Another whole-body modeling approach for NPs borrowed from free drugs is noncompartmental analysis (NCA)18,30,39,40. The method involves no compartmentalization of
the system and is a mathematical technique to estimate relevant PK parameters from
plasma concentration-time data without assuming any underlying model of compartments.

1.3. Tissue scale modeling
We now discuss relevant modeling works that focus on the tissue scale, with the tumor as
the tissue of interest. These models focus on different aspects of NP transport and help
understand the relationships between physicochemical properties of NPs and their
deliverability to the tumor tissue. These models are broadly of three types: agent-based,
continuum, and hybrid. This classification is based on the resolution of the model, i.e., in
agent-based modeling approach, the individual entities of the species of interest are
modeled explicitly, therefore limiting the size of the modeling domain under the availability
of a limited computational resource. On the other extreme is the continuum approach,
where bulk behavior of the system is taken into consideration and thus only macroscopic
predictions can be made. Hybrid modeling is an integration of the agent-based and
continuum modeling approaches. In this approach, the system is partially modeled as
agent-based and partially as continuum, which allows expanding the size of the modeling
domain without adding to the cost of the computational resources.
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Chauhan et al.41 developed a mathematical model of tumor vasculature based on
percolation theory42. The model is cast in the form of a two-dimensional percolation
network representing tumor vasculature with one inlet and one outlet to study the effect of
vascular normalization on tumor delivery efficiency of nanomedicine. The network consists
of a series of interconnected nodes representing blood vessel segments, with each
segment endowed with vessel wall pores obtained from a distribution of pore sizes. It is
assumed that blood flow in the vessels follows Poiseuille’s law, transvascular fluid
exchange occurs according to Starling’s approximation, and Darcy’s law governs
interstitial fluid transport. Further, the transport of NPs across vessel wall pores is modeled
using ‘pore theory’ to determine barriers to diffusion and convection across cylindrical
pores. By capturing critical transport phenomena at the tissue scale, this model provides
insight into the significance of vascular normalization in nanomedicine. Further, they also
studied the effect of NP surface charge on transvascular flux of NPs and demonstrated
the superiority of cationic particles in crossing into the tumor interstitium.43 But, for this
investigation they used a mathematical model of tumor vasculature based on a previously
developed algorithm of tumor-induced angiogenesis governed by vascular endothelial
growth factors and fibronectin gradients44. However, the approximations and assumptions
of fluid and NP transport in this model remain the same as the percolation network model,
except that the vascular network formation is more physiologically based. The group
expands the percolation network model45 further to incorporate controlled release of drugs
from NPs and their binding and internalization into tumor cells, to study efficacy of NPdelivered chemotherapy on cancer cells. They mathematically formulate the interstitial
processes of drug release from NPs, drug diffusion, cell surface bonding, and cellular
internalization in the form of coupled partial differential equations (PDEs) to model the
evolution of internalized drug concentration and compare the cell-kill induced by a twostage and a multi-stage nanoparticulate system with conventional chemotherapy.
9

Papageorgis et al.46 used the same model to test the effect of drug-induced reduction of
mechanical stresses in tumors on improved efficacy of nanotherapeutics.
Hauert et al.47 modeled a representative section of tumor tissue to study design
characteristics of targeted NPs responsible for binding site barriers48 and propose
guidelines to overcome such barriers. The modeled section represents a hypoperfused,
near-necrotic region of the tumor where NPs extravasating form the microvessels diffuse
into surrounding tumor tissue, may bind to surface of cells, and internalize into cells.
Reaction-diffusion kinetics thus forms the basis of such a model, and is represented by
,

the following biochemical reaction: 𝑁𝑃 + 𝑅 ⎯ 𝐶 → 𝑁𝑃 + 𝑅, where 𝑁𝑃 represents free
NPs, 𝑅 refers to cell-surface receptors, 𝐶 are the NP-receptor complexes, 𝑁𝑃 represents
internalized NPs, and 𝑘 , 𝑘 , and 𝑘 are the association, dissociation, and internalization
rate constants, respectively. Two different approaches have been used to model this
system: i) deterministic and ii) stochastic. The deterministic modeling approach comprises
of coupled reaction-diffusion PDEs governing the spatiotemporal evolution of species of
interest (𝑁𝑃 , 𝑅, 𝐶, 𝑁𝑃 ) in one-dimensional domain. On the other hand, the stochastic
modeling approach discretizes the spatial domain into cubes with side 𝑆, assuming a wellmixed volume in each unit. NPs diffuse across these sub-volumes while interacting with
surface receptors, forming complexes, and undergoing internalization, with each event
being governed by a dynamic probability. They employ the equivalent of Gillespie’s
Stochastic Simulation Algorithm49 in an open access Stochastic Simulation Complier
(SSC)50 to simulate the biochemical reaction network and thus obtain the evolution of each
species of interest over time. The stochastic model captures the randomness and
fluctuations of a biochemical system, unlike the deterministic model, however the latter is
a better choice for systems with large populations and relatively small fluctuations, since
the SSC might be computationally expensive for such systems. Thus, in this paper the
10

authors use the deterministic model to simulate different experiments and only validate
key findings using the stochastic model. Their work suggests delaying the binding of NPs
to target cells to avoid binding site barriers and allow them time to penetrate deep into the
tumor tissue, which can be achieved by engineering NPs to avoid premature cellular
uptake.
Sykes at al.51 performed Monte Carlo simulations to study diffusion of NPs through
tumor extracellular matrix (ECM), based on the approach of Stylianopoulos et al. 52. They
computationally model the tumor ECM in three-dimensions as an anisotropically oriented
network of collagen fibers (the most abundant protein-type in ECM) to study the mobility
of NPs through matrices of different collagen densities. Collagen fibers are approximated
as immobile cylinders and NP-fiber collision is assumed to be elastic. The model also
assumes a dilute concentration of NPs to neglect NP-NP collisions. NP movement is
simulated as a discrete random walk following Stokes-Einstein relation for diffusion of
spherical particles in a fluid with low Reynolds number. They also modeled in 2D the
microscopic collagen matrix pores to study the effect of NP size and matrix pore size on
the frequency of NP-fiber collisions to provide a mechanistic explanation to the results of
the 3D model. In this model, a pore is represented by a square bounded by collagen fibers
and a NP undergoes 2D Brownian motion inside the square, and the particles are tracked
for their collisions with the wall (fibers). Their models explain the mechanisms underlying
particle size-dependent retention of NPs in clinically relevant tumor conditions.
In order to establish the mechanism of clearance of hard-nanomaterials by the
liver, Tsoi et al.53 developed a minimal model of the liver sinusoid and studied the role of
flow dynamics and NP physicochemical properties on sequestration of NPs in the region
of interest. The sinusoid is modeled as a cylindrical channel of length 𝐿 and radius 𝑟 , with
cells, capable of sequestering NPs, lining the wall of the channel. NPs flow in the channel
11

under the influence of pressure gradient-driven advection along the longitudinal axis and
Brownian motion along the radial axis. The model is expressed as a PDE that defines the
temporal evolution of density of NPs along the length of the channel. The PDE is then
solved to obtain an expression for the probability 𝑃 of NP sequestration in the channel,
given by 𝑃 = ∑

[1 − exp(−

𝜆 )]𝑏 , where 𝐷 is NP diffusivity and 𝑈 is the average flow

velocity. 𝜆 and 𝑏 are numerical coefficients that depend upon flow profile and boundary
conditions. In this expression,

resembles inverse of the Peclet number (1/𝑃 ) and is a

ratio of the rate of diffusion to rate of advection that controls the extent of interaction of
NPs with the channel walls. Hemodynamic conditions, and particle properties, that lead to
≫ 1, favor greater NP sequestration in the channel, explaining the underlying
mechanism for high NP sequestration in liver. Further, to account for the effect of NP-cell
pair properties on cellular internalization of NPs and to not assume the cells to be a perfect
trap, a sticking coefficient (ratio of dissociation constant to association constant) is
introduced into the model, thus making the model predictions more reliable.

1.4. Integrative multiscale modeling
Multiscale modeling integrates different relevant scales and is thus an important tool to
comprehensively study the behavior of NPs. Multiscale models are typically hybrid in
nature and thus leverage on the strengths of both agent-based and continuum modeling
approaches. We discuss some representative multiscale models developed to study
efficacy and safety of nanomedicine.
Frieboes at al.54 developed a computational model to predict accumulation of NPs
in tumor vasculature. It combines a previously developed two-dimensional model of tumor
growth and angiogenesis44,55-58 with a mesoscopic model of NP adhesion to the tumor
neovasculature. Tumor dynamics are primarily governed by cell division, cell death, cell
12

migration, and cell adhesion (to other cells and to extracellular matrix). The above
processes are accounted for in the tumor growth compartment as a mathematical model
based on conservation principles (mass, momentum) and transport phenomena (diffusion,
convection). Tumor growth model is then coupled with a model of tumor-induced
angiogenesis based on tumor angiogenic factor (TAF) gradients (same as used in the
previously discussed model43). This component accounts for tumor blood flow, nonNewtonian effects, vascular leakage, and vasculature remodeling due to shear stress and
mechanical stress because of a growing tumor, thus simulating a pathophysiologically
relevant scenario to test neovascular accumulation of systemically injected NPs based on
a mesoscopic mathematical formulation. This mesoscale formulation accounts for the
opposing dislodging and adhesive forces at the NP-endothelial cell interface. A force
balance between hemodynamic forces, specific receptor-ligand interactions, and nonspecific forces (van der Waals, electrostatic, steric) acting on the NP governs the
probability and strength of adhesion of NPs to vasculature.59 Thus, by integrating the
evolution of a growing tumor with NP-cell interactions, the model demonstrates the
dependence of vascular accumulation of NPs on tumor growth stage, in addition to the
importance of NP vascular affinity in controlling total accumulation of NPs and their spatial
distribution inside a tumor.
A multiscale hybrid model was developed by Laomettachit et al.60 to assess NP
toxicity in human liver. The model uses a standard whole-body PBPK framework to predict
hepatic accumulation of administered NPs and feeds the information into a tissue scale
‘cell-response model’ of liver tissue. The cell-response model accounts for cell division
and cellular uptake of NPs to predict the impact of NPs on hepatocyte viability. This
multiscale platform demonstrates the dose-dependent toxicity of TiO 2 NPs in liver.
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1.5. Motivation and scope of this dissertation
To develop nano-therapeutics and diagnostics of clinical relevance, it is critical we
understand their pharmacokinetic behavior so as to make predictions about the cargodeliverability and off-target accumulation of the injected nanocarriers. This is critical to be
able to design NPs with reduced off-target accumulation, optimal bioavailability, and good
clearance behavior, for a potential clinical application. We thus employ in vivo and human
histological studies to gain information about in vivo NP behavior along with physiological
characteristics of the tissue of interest to develop pharmacokinetic models that improve
our understanding of NP kinetics.
The first modeling approach is a whole-body continuum approach based on in vivo
imaging studies in healthy rats and helps us establish the relationship between NP
physicochemical properties and their in vivo disposition. Our simplistic mathematical
approach allows us to formulate readily usable master equations in closed-form to be
employed to multi-organ NP kinetics. Moreover, it allows us to extract meaningful
quantitative pharmacokinetic information for clinically relevant NPs in the size range of 25150 nm, and allows us to make predictions on the potential applications of such nanoformulations, based on their whole-body biodistribution patterns.
This is followed by the development of an integrative multiscale pharmacokinetic
model, which can serve as an in silico tool to test various NP size and surface
characteristics and predict the spatiotemporal evolution of their concentration in major
organs of interest and a solid tumor. This model is parameterized with human
physiological values and thus serves to make predictions for nanomedicine deliverability
in human tumors, and off-target accumulation and clearance.
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We first begin by reviewing literature on the applications of mathematical modeling
in understanding drug resistance in breast cancer and discuss the potential of
nanomedicine in overcoming such barriers.
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Chapter 2 – Understanding drug resistance in breast cancer with
mathematical oncology

This chapter was adapted from:
Dogra, P.*, Brocato, T.*, Koay, E.J.*, Day, A., Chuang, Y.L., Wang, Z., Cristini, V.
Understanding drug resistance in breast cancer with mathematical oncology. Current
Breast Cancer Reports 6.2 (2014): 110-120. (*Authors contributed equally to this work)
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2.1. Abstract
Chemotherapy is mainstay of treatment for patients with breast cancer, but results in only
26% of patients with distant metastasis living 5 years past treatment in the United States,
largely due to drug resistance. The complexity of drug resistance calls for an integrated
approach of mathematical modeling and experimental investigation to develop
quantitative tools that reveal insights into drug resistance mechanisms, predict
chemotherapy efficacy, and identify novel treatment approaches. This paper reviews
recent modeling work for understanding cancer drug resistance through computer
simulations of molecular signaling networks and cancerous tissues, with a particular focus
on breast cancer. These mathematical models are developed by drawing on current
advances in molecular biology, physical characterization of tumors, and emerging drug
delivery methods (e.g., nanotherapeutics). We focus our discussion on representative
modeling works that have provided quantitative insight into chemotherapy resistance in
breast cancer and how drug resistance can be overcome or minimized to optimize
chemotherapy treatment. We also discuss future directions of mathematical modeling in
understanding drug resistance.
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2.2. Introduction
Breast cancer is a major cause of death in women in the United States and globally

61

The lethality of this disease is related to its robust ability to resist anticancer therapies

62

.
.

Drug resistance, either acquired or intrinsic, is believed to cause 90% of all chemotherapy
failures, and the 5-year survival rate for metastatic breast cancer in United States is only
26%

63,64

. Multiple biological factors are believed to cause drug resistance, including

genetic alteration, bypass mechanisms, altered effectors in DNA repair, pathway
independent acquired resistance, pH alterations, and up-regulation of efflux pumps in
cellular membranes 64-66. Another very important, but less-discussed reason that operates
at a higher scale of organization is the existence of physical barriers that limit diffusive and
convective drug transport in the required lethal drug concentrations to the regions of
interest. The presence of dense extracellular matrix and interstitial hypertension in the
tumor microenvironment and hostile conditions, marked by hypoxia and hyperacidity,
affect drug penetration and drug efficacy respectively 67-69.
Mathematical modeling has been widely used as a method complementary to
experimental investigations to provide insight into cancer initiation, progression, and
invasion in the past several decades 70,71. Its importance is increasingly recognized for its
capability to interpret and integrate the massive amount of data that experimental
biologists are currently producing, especially in the era of data-intensive cancer research
72

. Modeling approaches can be briefly divided into three categories: discrete, continuum,

and hybrid, i.e., the combination of both (the reader can refer to 71,73-77 for recent excellent
reviews). Discrete models explicitly represent individual cells (or part of a cell or a cluster
of cells) in space and time, and then track and update their states and interactions
according to pre-defined computational rules derived from experimental data. In contrast,
continuum models represent the tumor as a continuous mass rather than as discrete
18

components, and give information about the overall tumor morphological behavior while
neglecting the influences of individual cells. By drawing on the strengths of both continuum
and discrete descriptions, hybrid modeling provides a more complete description of the
tumor and its microenvironment, hence having been accepted as the more desirable
choice. Regardless of the modeling technique used, computational oncologists should
note that the development of a successful cancer model is a long-term, integrative, and
iterative process, where available experimental data are used to guide the model design
and to validate the model.
Significant progress has been made in mathematical modeling of cancer drug
resistance to understand how biological and physical factors of the tumor influence
therapeutic outcomes. Mathematical models have applications that range from describing
drug delivery, predicting cell kill from cytotoxic therapies, and anticipating tumor growth,
among many others 78. The ability to predict tumor-related outcomes aids the interpretation
of experimental data and generation of specific biological/medical hypotheses. In this
review, we will discuss the progress that has been made in mathematically describing
fundamental processes in signaling networks and the tumor microenvironment,
highlighting how the physical sciences can contribute to our understanding and treatment
of breast cancer and other tumors.
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2.3. Molecular scale modeling
Overexpression of efflux pumps
Molecular level alterations and mutations can promote tumor formation and cellular drug
resistance

73

, which can cause hypersensitivity and overexpression of receptors,

promoting tumor cell proliferation. For example, P-glycoprotein overexpression effectively
lowers the intracellular concentration of chemotherapy, enabling cellular resistance to
toxic drugs. Atari et al.

79

studied drug resistance mechanisms of topotecan in breast

cancer based on efflux pumps and drug resistance proteins. The primary efflux pump
modeled, breast cancer resistance protein (BCRP), is known to be expressed in high
concentrations in membranes of resistant tumor cells. A quasi-steady nonlinear drug
kinetic model was developed in this study with consideration of a single cell’s
compartments, comprising the matrix, extracellular region, cell membrane, cytoplasm, and
nucleus. This model demonstrates that topotecan resistance can be predicted from BCRP
expression in the various compartments, which could aid the design of optimal dosing
regimens.

P-glycoprotein transfer between cells
Cell-to-cell transfer of P-glycoprotein from resistant cells to sensitive cells not currently
expressing P-glycoprotein is observed in cancer drug resistance 80. Pasquier et al. studied
the role of P-glycoprotein expression in MCF-7 breast cancer cells using time-dependent
mathematical model based on a continuum population density function

63

. The model

investigated and quantified how the overall drug resistance was affected by rates of cell
proliferation and death, P-glycoprotein induction and degradation, and P-glycoprotein
transfer between cells. Their simulation results showed that the transfer of P-glycoprotein
20

between breast cancer cells confers the multidrug resistance phenotype to cells not
expressing P-glycoprotein.

HER2 induced drug resistance
Breast cancer drug resistance of HER2 (human epidermal growth factor receptor; also
known as ErbB2) targeting agents, including monoclonal antibodies for HER2-positive
breast cancer, pertuzumab and trastuzumab, and/or a tyrosine kinase inhibitor, lapatinib,
have been well studied 81-83. Overexpression of HER2, found in 20-30% of breast cancers
84

, has a negative prognosis for survival 85. Faratian et al. used a systems biology approach

to formulate a kinetic model that is predictive of resistance in response to receptor tyrosine
kinase inhibitors. They found that the expression level of PTEN (a tumor suppressor
protein) is the only significant predictor of survival by treatment with trastuzumab

81

.

Kirouac et al. used a multiscale network-based pharmacokinetic and pharmacodynamics
model to determine the best combination treatment for HER2-amplified breast cancer cells
which resulted in the combination of trastuzumab, lapatinib, and an ErbB3 inhibitor, MM111 being the most effective of the combinations tested

82

. Application of this model in a

clinical setting will determine the best mixture of various chemotherapy drugs to minimize
resistance in HER2-positive breast cancer. Niepel et al. developed a mathematical model
based on partial least-squares regression method to determine ligands that predict the
response to treatment. Heregulin and ErbB3 were found to be good predictors of drug
response. Clinically this model can be used to determine biomarkers of drug sensitivity
and resistance

83

. Vera et al. also created a kinetic model which determined

chemoresistance based on genetic signatures of transcription factors E2F1 (positive
regulation of proapoptotic genes) and miR-205 (repression of antiapoptotic genes)
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86

.

Results of this model demonstrate that genetic signatures can predict chemoresistance,
helping to stratify patients for risk of therapy failure.

The effect of the cell cycle on chemotherapy
The cell cycle was found to play an important role in expression of P-glycoprotein and
drug resistance. Roe-Dale et al. 87 determined that breast cancer patients given sequential
drug treatment of doxorubicin (DOX) followed by CMF (cyclophosphamid, methotrexate,
and 5-fluoruracil) was more successful in reducing drug resistance than patients given
alternating amounts of CMF and DOX in cycles. Chemotherapy drugs are found to be toxic
in a cell-stage dependent manner, with DOX being more effective in the beginning and
late portions of the cell cycle, and the CMF drugs being most effective in the beginning of
the cell cycle. Specifically in

87

, modeling of the cell cycle and its effect on multidrug

resistance through the use of successful sequential drug treatment compares four ordinary
differential equation models (for drug treatment, cell cycle, drug resistance, and a
combination of cell cycle and drug resistance, respectively) to determine importance of
cell cycle and resistance on cell kill. The models included drug treatment model, cell cycle
model, resistance model, and cell cycle and resistance model. The cell cycle and
resistance model accounted for (1) cell cycle stage based on amount of DNA in a cell in a
given stage and (2) cell cycle and accumulation of drug sensitivity due to P-glycoprotein.
Their simulation results were consistent with patient and experimental data, with cellular
drug resistance having a bigger impact than cell cycle stage.
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2.4. Tissue scale modeling
Overview: Biophysical barriers to drug delivery and therapeutic resistance
Solid tumors (including breast cancer) are either drug resistant at initiation of
chemotherapy, or become resistant with the progression of therapy, arguably due to
selection pressure induced by cytotoxic agents on surviving cells

88

. As discussed in the

previous section, the molecular principles of drug resistance play an important role in
making cancerous cells refractory to treatment. Before these molecular/cellular
mechanisms come into picture, two very critical aspects contribute to therapeutic
resistance: drug delivery across the tumor, and the physiology of the tumor
microenvironment 69.
The tumor microenvironment can be divided into three components: (1) cancer
cells, (2) interstitium, which consists of stromal cells (fibroblasts and inflammatory cells)
and the extracellular matrix (ECM), and (3) tumor microvasculature

89

. This environment

is hostile to normal cells and is characterized by hypoxia, hypoglycemia, ATP depletion,
acidosis, denser than normal ECM, and elevated interstitial fluid pressure (IFP) compared
to normal tissue

69,90

. This biochemical environment affects cellular behavior and drug

chemistry, enabling tumor cells to survive chemotherapy. The microenvironment also
poses a direct barrier to drug delivery. After a drug reaches the tumor microvasculature,
extravasation from the microvasculature is the first challenge to overcome to enter the
tumor interstitium 91. Subsequently, drug molecules must penetrate through the abnormal
tumor interstitium, cross the individual cancer cell membranes and eventually reach their
sub-cellular targets. The transit from within the microvasculature to the inside of a cell is
accompanied by biophysical and biochemical barriers of the microenvironment, and
molecular barriers of cancer cells. Thus, the tumor microenvironment confers drug
resistance in two ways, biochemical gradients and biophysical barriers
23

67-69,88

.

As a tumor grows in its vascular growth phase in a confined volume, it faces two
kinds of solid stress: external stress and residual stress, applied by surrounding normal
tissue and by the growing tumor, respectively. This stress is of the order of 1.3-13.0 kPa,
sufficient enough for causing the collapse of blood and lymph microvessels. Vascular
collapse of lymphatics leads to poor extracellular fluid drainage, while collapse of blood
microvessels has implications for poor drug delivery and transport of oxygen, nutrients,
etc.

92,93

. As indicated previously, tumor vasculature is drastically abnormal compared to

healthy tissues. The “leaky” nature of tumor vasculature has been exploited in the passive
targeting of drugs

94

, but a downside of this leakiness is the development of interstitial

hypertension. Due to vascular hyperpermeability and poor lymphatic drainage, particularly
at the center of the tumor, excess fluid accumulates in the interstitium, elevating the IFP.
IFP equilibrates with microvascular pressure which nullifies the pressure gradient required
for extravasation of drug molecules on account of convection with the outgoing fluid. Thus,
elevated IFP is a formidable barrier to convective transport, limiting the drug molecules
from exiting the vascular compartment

95,96

, and tends to exert an isotropic fluid-phase

stress that also has direct implications for vascular collapse

92,97

.

Following extravasation, the penetration through tumor interstitium occurs
primarily via drug gradient-driven passive diffusion, and to some extent through
convection. Usually, IFP tends to diminish pressure gradients on account of its fairly
uniform elevation across the tumor, thus diffusion remains the major determinant of
interstitial migration of drug molecules

96

. However, diffusion of molecules through the

interstitium to reach tumor cells at a distance from blood vessels is met by immense
physicochemical resistance which tends to hamper drug distribution

67,68,98

. Diffusion

barriers within the interstitium occur on account of factors, such as cellular adhesion,
dense packing of tumor cells, composition of ECM, solid and fluid stress, and large
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distances between vessels 99. The physicochemical properties of drugs, such as size and
charge also affect their passage through the interstitium on account of their electrostatic,
hydrodynamic, and steric interactions with the ECM 100.

Clinical trials assessing drug delivery and transport
Several trials have analyzed drug delivery in patients to variable degrees of sophistication
to understand the factors that influenced how much drug reached the target. For example,
gemcitabine delivery was measured for patients with squamous cell cancers of the head
and neck

101

, but factors related to delivery were not assessed in this trial. The main goal

of delivery measurement was to determine whether specific doses of gemcitabine were
sufficient for detectable delivery. The transport-related changes after anti-angiogenic
therapy have also been assessed, supporting the hypothesis of vascular normalization 102.
In a study conducted in breast cancer patients treated with doxorubicin, it was seen that
drug did not reach all parts of the tumor tissue, and gradients were established with more
drug in the periphery of the tumor than its center. This effect was more pronounced in
tumors with dense packing of cancer cells 103. The effects of paclitaxel and doxorubicin on
interstitial fluid pressure and oxygenation were measured in a trial of neoadjuvant
chemotherapy for patients with breast cancer, showing that paclitaxel improved the
transport properties of the tumors while doxorubicin did not. This provides rationale to
optimize the sequence of chemotherapies 102. In another study done on mouse models of
various solid tumors, similar trends of exponential decrease in doxorubicin concentration
with increasing distance from nearby blood vessels were observed

104

. These studies

demonstrate non-uniformity of drug distribution across the tumor and indicate potential
involvement of biophysical barriers in thwarting chemotherapy.
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We published a first-in-kind clinical trial of intraoperative gemcitabine infusion for
patients with resectable pancreatic cancer

105

. The objectives were to measure the

incorporation of gemcitabine into the DNA of tumor cells and understand the factors that
influence delivery. We used semi-quantitative scoring of the pathology to assess stromal
score and the staining levels of the cellular transporter of gemcitabine, hENT1

106

, which

may be associated with outcome in pancreatic cancer. We also developed a mathematical
model to describe the changes in density during routine contrast-enhanced computed
tomography (CT) imaging of patients with pancreatic cancer. We discovered that
gemcitabine delivery to the cellular DNA could be described by multi-scale transport
phenomena, as characterized by both the stromal score and hENT1 levels. Furthermore,
the CT-derived transport properties also correlated with the drug delivery. We extended
our CT transport analysis to 110 patients who received protocol-based neoadjuvant
gemcitabine-radiation for resectable pancreatic cancer, and found that the pre-therapy
CT-derived transport properties correlated with pathological response and survival. Thus,
transport properties of pancreatic cancer describe the delivery of, response to, and
survival after gemcitabine-based therapies.
Extending these methods to patients with breast cancer would help identify the
major biophysical barriers to drug delivery. Such efforts could aid the design of new
therapeutic strategies that overcome these physical impediments. If combined with
mathematical oncology approaches, these clinical trials could provide a mechanistic
understanding of drug delivery for each patient. We will highlight some of these
mathematical models.
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Vascular supply of drugs
A mathematical model by Sinek et al.

107

accounted for the morphologic and vascular

heterogeneity of tumors, and predicted the effectiveness of anticancer agents. The model
employed a multiscale tumor growth and angiogenesis simulator 108 based on an adaptive
finite element mesh by Cristini et al.

109

for simulating tumor growth and response to

chemotherapy administration. Simulation results showed that tumor microenvironmental
factors relevant to drug, oxygen, and nutrient distribution led to variations in tumor
response to chemotherapy, implicating this variable drug delivery as a cause of
therapeutic resistance. This model can potentially serve as a tool for predicting in vivo
pharmacokinetics of anticancer agents.
Baish et al. 110 developed a mathematical model using fluorescent vascular images
to determine the effect of architectural, physiological and branching irregularities of tumor
vasculature on the delivery of therapeutic agents and nutrients. By calculating δmax
(maximum distance from the nearest blood vessel) and λ (a measure of shape of voids
between vessels) from vascular images, the authors showed that the model predicted the
amount of “material” (e.g., nutrients and therapeutic drugs) and the time required for the
material to reach its destination. The model predicted diffusion in irregularly shaped
domains and evaluated the efficacy of therapeutic agents that induce “vascular
normalization”

111

. This mathematical model accounted for the existence of diffusion

barriers pertinent to irregular vasculature and can be used to quantify the effect of such
impediments on drug delivery. Thurber et al.

112

also developed a model using in vivo

images of drug distribution around tumor vasculature from murine tumor models. Their
model predicted drug distribution profiles along the vasculature with intermittent blood
flow. This model may be used as an assessing tool for predicting conditions where tumors
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may not receive therapeutic amounts of administered drug in clinical practice, and thus
might be inclined to resistance.

Transvascular extravasation of drugs
Stapleton et al. 113 modeled convective drug transport across tumor microvasculature and
tumor interstitium to study the transport of liposomal drug delivery that implements the
enhanced permeation and retention (EPR) effect by accounting for transvascular and
intersititial fluid dynamics

114

. The model provided a theoretical framework for predicting

intra-tumor and inter-subject variations in liposomal accumulation due to variations in EPR
based on microenvironmental physiological factors. Wu et al.
developed vascular tumor growth model

115

55

extended a previously

by incorporating IFP and interstitial fluid flow

(IFF), lymphatic drainage, and vascular leakage. The model revealed the effects of
elevated IFP on drug, nutrient and oxygen extravasation, and tumor growth, as it indicated
that interstitial pressure caused microvascular collapse and influenced tumor growth
through nutrient and oxygen deprivation.
The extravasation of molecules tends to be affected by steric, hydrodynamic and
electrostatic interactions between molecules and pores of leaky vessels. Stylianopoulos
et al.

43

studied interactions between nanoparticles and negatively-charged pores to

predict the existence of an optimum value of surface charge density. The model was
applied to various sizes of nanoparticles and found that for every nanoparticle size, there
is a value of surface charge density above which electrostatic forces become dominant
and leads to a steep increase in transvascular flux. Such a mathematical model would
play a critical role in guiding the design of nanotherapeutic formulations for anticancer
drug delivery.
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Drug diffusion through tumor interstitium
Stylianopoulos et al. 52,116 modeled the tumor interstitium to predict the effects of repulsive
electrostatic interactions and fiber network orientation on the diffusion of charged drug
molecules through the matrix. Their model predictions suggested that electrostatic
interactions between fibers and drug molecules/nanoparticles tended to slow down
diffusion. This prediction explained the observation that neutral particles diffuse faster in
comparison to charged particles. Simulating fiber network orientation with varying degrees
of fiber alignment, their analysis demonstrated that the overall diffusion coefficient was not
affected by network orientation; however, diffusion anisotropy was predicted as a result of
structural anisotropy. Diffusion anisotropy becomes even more significant with increasing
degree of fiber alignment, particle size, and fiber volume fraction.
As an extension to a three-dimensional multispecies nonlinear tumor growth model
by Wise et al.

117

, Frieboes et al.

118

developed a model based on in vitro spheroids and

monolayers of breast cancer cells that incorporates the biophysical barriers for drug and
nutrient diffusion and provides a quantitative relationship between tumor phenotype and
its response to chemotherapy. The model simulates impeded diffusion of drug, oxygen
and nutrients, and correlates it to poor response to chemotherapy on account of both poor
drug delivery and lack of nutrients required for cellular proliferation. The model can be
instrumental for clinical use in predicting the effect of chemotherapy on a tumor of known
phenotype. Das et al.

119

also modeled the three-dimensional aspects of the tumor

microenvironment in the context of the diffusion of interferon-γ through the tumor
interstitium. The mathematical model predicted the limited success of immunotherapy in
breast cancer on account of the diffusion barriers.
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Recently, Pascal et al. 120 developed a mathematical model based on the physical
laws of diffusion to predict the fractional tumor killed due to chemotherapy. The important
parameters in the model were volume fraction occupied by tumor blood vessels and their
average diameter, as measured from histopathology. Drug delivery to cells and
subsequent tumor cell kill were assumed to be mediated by these microenvironmental
properties. The model predicted tumor cell kill in colorectal liver metastases and
glioblastoma, using patient-specific histopathology data (Figure 2-1). Thus, it can be used
to develop individualized treatment strategies that account for the amount, frequency, and
delivery platform of drugs and other cytotoxic therapies.

Biochemical gradients within tumor microenvironment
For cancer cells to remain alive and actively dividing, it is critical that their metabolic
requirements be met. When the metabolic load supersedes the supply of oxygen and
nutrients, hypoxic tumor cells tend to induce angiogenesis to maintain a constant supply
of oxygen and nutrient rich blood. Despite neovascularization, there is a continual gap
between demand and supply; aggressive tumors might have high microvascular density
but still have significant hypoxia and acidosis due to inadequate perfusion

121

. Due to

aberrations in the vessel wall integrity, tumor blood tends to become hyperviscous. As a
result of solid and fluid stress within the tumor, vascular collapse can occlude the flow of
blood, leading to high resistance to blood flow and thus insufficient perfusion.
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Figure 2-1: Results of fitting the model to patient data by a regression analysis.
Fraction of tumor killed f kill and thickness of dead tumor regions rk were measured in 49
histopathological sections of colorectal cancer metastatic to liver after chemotherapy.
Quadratic least-square fit (dashed curve; R2 = 0.92) and least-square fit (red curve; R2 =
0.94) of the model are shown. Biologically realistic parameter values obtained from the fit
are shown in the inset table. BVF: blood volume fraction; rb: blood vessel radius; and L:
diffusion penetration distance. This analysis demonstrates that the model agrees with the
distribution of the patient data. Adapted with permission from
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120

.

The distribution of tumor vasculature within the tumor is heterogeneous, creating
anisotropy in perfusion in terms of both space and time. As a result of heterogeneity of
blood perfusion, drug does not reach uniformly to all parts of the tumor leading to a
population of cancer cells being untouched, or only moderately touched by the cytotoxic
agent. Tumor tissue tends to develop gradients of oxygen level, pH, glucose, ATP and
rates of cancer cell proliferation across the tumor. A direct implication of hypoxia is G 1/Sphase cell cycle arrest

122

. Due to low extracellular pH, weakly basic drugs tend to get

protonated and exhibit lower cellular uptake 123,124. Eventually these biochemical gradients
result in reduced sensitivity to cell cycle specific cytotoxic agents
mathematical model

126

125

. In extension to a

that predicted the extent and location of quiescent cells in

multicellular spheroids, Venkatasubramanian et al. 127 incorporated cell cycle progression,
nutrient and drug transport limitations, and pharmacodynamics and pharmacokinetics to
predict the effect of tumor microenvironmental heterogeneity and hostility on drug
cytotoxicity. Their simulation results suggest a therapeutic strategy: optimizing molecular
weights of drug molecules to reach an optimum diffusion coefficient that is neither too
small to be cleared from blood before effective penetration, nor too large to limit effective
drug retention.

Overcoming physical barriers with nanotherapeutics
Current standard therapies for breast cancer are efficacious to a limited extent

119

.

Nanotherapies may confer advantages over conventional drugs in overcoming therapeutic
resistance. Possible advantages include delivering higher concentrations of drug,
promoting greater drug uptake by tumor cells, overwhelming drug efflux pumps,
accumulating drug in tumor vasculature, and causing less toxic effects on the patient 54,128.
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Silica nanovectors with doxorubicin were able to overcome therapeutic resistance and
outperform traditional therapies against hepatocellular carcinoma in vitro because of their
ability to carry much higher concentrations of drug. This promoted a higher amount of
overall drug uptake and greater overall cell kill

129

. Nanoparticles (NPs) also use far less

drug overall, allowing for the potential to deliver larger quantities of NPs or even higher
concentrations with still fewer negative cytotoxic effects

130

. A study done with

osteosarcoma found that NPs loaded with doxorubicin were more effective because they
had higher levels of accumulation in solid tumors and they were able to deliver drug to the
nucleus of the tumor cells

131

. This accumulation may be attributed to longer circulation

times due to their small size and specific surface ligands. These small NPs can specifically
target tumor endothelium with low or high affinity, enabling them to distribute throughout
the tumor, or accumulate at the inlet depending on which is desired in a specific treatment
54,128

. Many researchers also contribute NPs effectiveness to its ability to circumvent

therapeutic resistance efflux pumps such as P-glycoprotein, preventing drug loss from
tumor cells 129,131.

2.5. Conclusions
Mathematical models of drug resistance are summarized in Table 1. These efforts have
produced encouraging results in understanding cancer drug resistance, as seen in other
research areas such as identification of novel therapeutic targets

132-134

, development of

alternative therapeutic strategies 135, and prediction of surgical volume and tumor size 136.
Eventually, these data-driven models could help improve patient outcomes and reduce
costs of cancer treatment. However, the results reported to date based on mathematical
methods have not been sufficiently accurate or particularly helpful for clinical use. Here,

33

we discuss some directions in applying this type of integrated experimental and systems
modeling approach in understanding drug resistance in cancer.

Multiscale modeling
Cancer results from multiple genetic, epigenetic, and environmental factors in a
developmental context across a number of biological scales in time and space

70

. Hence,

understanding cancer drug resistance mechanisms by mathematical modeling should not
be limited to any specific biological scale, whether it is at the molecular level (gene, protein,
or signaling network) or higher, such as a tissue or organ level. By integrating data from
multiple levels of biological complexity, modeling tumor resistance to chemotherapy drugs
across different scales can potentially be more powerful in guiding the development of
new treatment strategies. In this perspective, by taking into account important oncological
characteristics such as individual and collective cellular activities, tumor heterogeneity,
and the changing heterogeneous microenvironment, a multiscale model of drug resistance
may provide a new means of predicting the overall tumor drug resistance behavior in
responding to changes that occur on any biological scale. This research has not yet been
fully explored in the field. It is also noteworthy that the development of a successful cancer
model of drug resistance is a long-term process, and that available experimental data
should be used to guide the model design and to verify and validate model results.
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Table 1: Summary of mathematical models addressing drug resistance in cancer at
different scales.
Phenomenon

Source

Major finding

Clinical relevance

Overexpression

Atari et al.79

In vitro topotecan

Provides framework

resistance can be

for in vivo studies to

determined by aldehyde

predict topotecan

dehydrogenase

resistance for breast

concentration and

cancer based on

expression of the efflux

parameters

pump, BCRP

measured

P-glycoprotein transfers

Predicts population

transfer

between cells to confer

of resistant cells and

between cells

resistance to cells not

framework for how

expressing the efflux

resistance spreads

pump

in breast cancer

Tumor suppressor

Predicts survival of

protein (PTEN) is only

treatment for HER2

significant predictor of

positive breast

resistance in patients

cancer

Combination of drugs is

Predicts optimal

required to be most

drug combinations

effective against

necessary to

resistance

overcome

of efflux pumps

P-glycoprotein

HER2-induced

Pasquier et al.63

Faratian et al. 81

drug resistance

Kirouac et al. 82
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resistance in HER2
positive breast
cancer
Niepel et al. 83

Heregulin and ErbB3

Predicts biomarkers

concentrations are good

that can be used in

predictors of cell

clinical setting to

sensitivity to anti-HER2

determine drug

drugs

sensitivity and
resistance

Vera et al. 86

Chemoresistance

Predicts resistance

determined by genetic

caused by genetics

signature of E2F1, MiR205, and the genes they
target
The effect of

Roe-Dale et al. 87

A model considering

Predicts that

cell cycle on

both cell cycle and

sequential ordering

chemotherapy

cellular drug resistance

of drugs in

was most consistent with

chemotherapy will

patient chemotherapy

be more effective

outcomes, sequential

than alternating

drug treatment was

between drugs

found to be the most
effective chemotherapy

36

compared to alternating
drugs
Vascular supply

Sinek et al. 107

of drug

Microenvironmental

Predicts in vivo

factors relevant to drug,

pharmacokinetics

oxygen, and nutrient

and efficacy of

distribution lead to

some anticancer

variations in tumor

agents

response to
chemotherapy
Baish et al. 110

Architectural and

Predicts efficacy of

physiological

vasculature

irregularities of tumor

normalizing agents

vasculature affect drug
and nutrient delivery to
tumors
Thurber et al. 112

At current clinical doses,

Predicts clinical

virtually all cells in a

conditions when

human tumor (> 99%

sub-therapeutic

including cancer and

concentrations of

non-cancer cells) should

drug is achieved

attain therapeutic drug
concentrations
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Transvascular

Stapleton et al.

Variations in inter-

Predicts intra-

extravasation

113

subject heterogeneity of

tumoral and inter-

liposomes are related to

subject variations in

heterogeneity of peak

liposomal

interstitial fluid pressure.

accumulation due to
variations in EPR
based on
microenvironmental
physiological factors
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Translational clinical trials
Understanding drug resistance through the use of mathematical modeling will help in
tailoring medical care to each patient. Carefully designed clinical trials that specifically
integrate a mathematical oncology component are needed to achieve this goal. Currently,
radiological and pathological data are not fully utilized in most clinical trials for correlative
studies. We have shown how both sources of data can reveal critical insights into the
physical mechanisms of drug delivery and cytotoxicity

105,120

. These individualized

approaches using physics can complement efforts to personalize treatment based on
biological factors specific to an individual (genes, proteins, environment)

137

, which has

been the major focus of correlative studies of most clinical trials. As we move toward an
era of integrated, personalized cancer care, it will be imperative to combine biological and
physical sciences to circumvent drug resistance mechanisms in the effort to cure cancer.
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Chapter 3 – Whole-body scale continuum modeling approach
This chapter was adapted from:
Dogra, P.*, Adolphi, N.A.*, Wang, Z.*, Lin, Y.S., Butler, K.S., Durfee, P.N., Bearer, E.L.,
Cristini, V., Brinker, C.J. Establishing the effects of NP physicochemical properties on in
vivo disposition using imaging-based pharmacokinetics. In review Nature Nanotechnology
(*Authors contributed equally to this work)

3.1. Abstract
The prospects of NP (NP)-based drug delivery and imaging have been hindered by
insufficient understanding of the effects of NP physicochemical properties on their in vivo
disposition. Using stable, monosized, radiolabeled mesoporous silica NPs (MSNs), we
apply an integrated SPECT/CT imaging and mathematical modeling approach to
understand the relationship between NP physicochemical properties and their
biodistribution and clearance kinetics, under intravenous or intraperitoneal routes of
administration, in healthy rats. We developed simple master equations in closed-form to
accurately represent the time-dependent concentration of MSNs in different regions of the
body and obtain functional relationships for predictive purpose to support rational design
of nanomedicine. Analyses revealed that an incremental increase in particle size between
~32 and ~142 nm results in a monotonic but non-linear decline in systemic bioavailability
of MSNs, as observed from the radioactivity washout in heart, irrespective of route of
administration (𝐴𝑈𝐶

= 𝜆 ∙ 𝑠𝑖𝑧𝑒

). Correspondingly, this effect is accompanied by

increased accumulation of MSNs in liver and spleen (𝐴𝑈𝐶
𝑠𝑖𝑧𝑒

.

. .

= 𝜆 ∙ 𝑠𝑖𝑧𝑒; 𝐴𝑈𝐶

. .

=𝜆∙

). Further, cationic MSNs with surface exposed amines are shorter lived in systemic

circulation, compared to MSNs of identical size and charge but with shielded surface
amines, due to rapid sequestration into liver and spleen. Positively charged MSNs show
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greater excretion than their size-matched neutral counterparts. Overall, our results
indicate that ~32 nm sized neutral MSNs can be promising candidates for delivery to
tumors via the EPR effect or to circulating, disseminated cells due to their avoidance of
uptake by the mononuclear phagocytic system organs, liver and spleen, which serve as
sinks for NPs, and their low excretion rates resulting in comparatively prolonged systemic
residence.
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3.2. Introduction
Whereas the potential of nanocarriers as effective drug delivery vehicles and imaging
agents has been established extensively in vitro, NP-based delivery has achieved only
moderate success in clinical translation, especially for therapeutic nanomedicines 1,138.
According to a comprehensive review surveying the literature from the past 10 years, the
in vivo tumor delivery efficiency of nanocarriers, which has relied primarily upon the EPR
effect, has averaged around only 0.7% of the injected dose139. This has been attributed to
uncontrolled, non-specific interactions of NPs with the immune and microanatomical
components of non-tumor sites, particularly the mononuclear phagocytic system (MPS)
organs, liver, spleen, and bone marrow, that serve as ‘sinks’ for preferential NP
accumulation.140 This is highly problematic as clinical translation of nanotherapeutics
demands a custom, reproducible disposition (biodistribution and clearance) profile of NPs
needed to achieve the requirements of efficacy and safety. For instance, the U.S. Food
and Drug Administration (FDA) guidelines require that diagnostic agents be completely
cleared from the body in a reasonable timeframe4. In contrast, it is particularly desirable
to have prolonged systemic circulation of chemotherapy-loaded NPs for maximal
exposure to tumor tissue and accumulation by the EPR effect 141. Literature stipulates that
a hydrodynamic size of < 5.5 nm and a positive zeta potential promote rapid renal
clearance of NPs, which is ideal for diagnostic applications4,142, but also that solid NPs
exceeding 6 nm in diameter cannot be renally cleared, now showed to be untrue (see
below). For therapeutic applications, e.g. cancer nanotherapy, polymeric coatings, like
polyethylene glycol (PEG) that serve to reduce serum protein adsorption (opsonization)
on the NP surface, are proclaimed to enhance the longevity of NPs in circulation, ideal for
increased exposure to the tumor141,143, but so far the tumor targeting efficiency of largely
PEGylated NPs has been modest and highly variable139.
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We contend that the deficiencies of NP therapeutics and the confusion in the
literature as to their efficiencies and behaviors are largely attributable to insufficient control
of NP synthesis and the lack of in vivo colloidal stability, which have led to inconsistent
biodistribution and therefore have prevented the establishment of definitive structureactivity relationships. So far, based on the ten year survey of NP delivery to solid tumors
previously cited, several trends have been observed with respect to NP physicochemical
properties: inorganic NPs have higher delivery efficiencies than organic NPs, NPs smaller
than 100-nm in hydrodynamic diameter have higher delivery efficiencies than larger
particles, nearly neutrally charged NPs (defined as having zeta-potentials -10 to +10mV)
have higher delivery efficiencies than more positively or negatively charged particles, and
rod-shaped particles are more efficient than spherical or plate-like particles. These trends
presumably reflect the in vivo stabilities of the NPs, differential uptake by the MPS, and
differences in renal clearance, however this survey did not establish unambiguously the
stability or size polydispersity of the NPs nor their biodistribution, and there appeared to
be no systematic studies to isolate the effects of size or charge or surface chemistry for
NPs of comparable composition and shape. Previous biodistribution studies have shown
that NP physicochemical properties, primarily size, charge, and surface polymeric
coatings144-147, along with routes of administration148-150 are critical in governing the
disposition kinetics of NPs, but again systematic studies are often lacking. Noteworthy in
this regard, we have recently demonstrated for NPs of identical size and charge, that the
spatial arrangement and accessibility of charged molecules on the NP surface (surface
chemistry) is another critical, but to date unrecognized, factor governing biological
behavior of NPs151.
Herein to establish quantitative NP structure-activity relationships in vivo, we
employed single photon emission computed tomography integrated with computed
tomography (SPECT/CT) imaging152 of 111In radio-labeled, monosized, mesoporous silica
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NPs (MSNs) to determine biodistribution in healthy rats. By systematically varying MSN
isolated physicochemical variables in the therapeutically relevant size range, 25-150 nm
(corresponding to physical diameter determined by TEM), we examined the effect of size,
zeta potential, and surface chemistry on in vivo disposition of hydrodynamically stable,
non-targeted MSNs administered via intravenous (i.v.) or intraperitoneal (i.p.) injection.
The selection of MSNs as the NP of choice for the current investigation is based on their
biocompatibility, high cargo-loading capacity, ability to undergo surface functionalization,
and precise synthesis control that allows for selection of particle size, shape, and pore
size, making MSNs ideal candidates for drug-delivery systems153-155. We employ
SPECT/CT imaging to determine the disposition kinetics of MSNs within ten regions of
interest (ROI) in the rat. We then developed a parsimonious, semi-mechanistic
mathematical model to describe the macroscopic concentration-time behavior of MSNs in
individual ROIs and estimate relevant pharmacokinetic (PK) parameters. Our results
allowed the formulation of significant correlations between particle physicochemical
properties and PK parameters, thus enabling quantitative comparison of the disposition
behavior of MSNs necessary to advance their status toward clinical use. An interplay
between physiological and NP physicochemical variables governs the in vivo behavior of
NPs, and this study furthers our understanding of this interaction.
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3.3. Methods
Synthesis and characterization of MSNs
The establishment of NP structure-activity relationships in vivo demands consummate
control of NP particle size, shape, surface chemistry, and stability. Here, to avoid
confounding effects of particle size polydispersity and hydrodynamic instability (which
have obscured the role of particle size in previous studies), we employed well
characterized, monosized (defined as hydrodynamic size polydispersity index (PdI) < 0.1),
PEGylated MSNs that exhibited long-term stability in physiologically relevant media (see
Methods in SI for details of MSN synthesis and characterization). 111In-labelled MSNs with
three different surface chemistries were synthesized with nominal diameter 50 nm: 1)
PEG-polyethylenimine (PEG-PEI), 2) PEG-quaternary amine (PEG-QA), and 3) PEGtrimethylsilane (PEG-TMS) (see schematic in Figure 3-1a). Additionally, PEG-TMS MSNs
were synthesized with nominal sizes: 25, 90, and 150 nm. The MSN core diameter was
determined by TEM and the hydrodynamic diameter and PdI were determined by dynamic
light scattering (DLS) (Figure 3-1b,c). Hydrodynamic diameter was consistently between
10 and 20 nm larger than the core TEM measurement, consistent with previous
observations in the literature156. MSNs showed excellent hydrodynamic stability in 1x PBS
over five to seven days (Figure S 1) where hydrodynamic diameter varied by less than 4.5%.
Surface charge of the particles was determined by measurement of the zeta potential (ζ).
PEG-TMS-modified particles were nearly neutrally charged (ζ = -4 to -7 mV), while PEGPEI- and PEG-QA-modified particles were strongly positively charged with nearly identical
zeta potentials (ζ = +37 to +38 mV) (Figure 3-1b). In fact, PEI- and QA-modified MSNs are
essentially indistinguishable according to the standard determinants of biodistribution
(core size, hydrodynamic size, shape, and zeta potential), however, as we will show, they
differ greatly in disposition (see below) due to differing distributions and exposures of
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surface amines (see schematic Figure 3-1a), consistent with previous observations of their
ex ovo behaviors within a highly vascularized chorioallantoic membrane model151.
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Figure 3-1: Characterization of MSNs, SPECT/CT imaging, and semi-mechanistic
modeling.
a, Schematic representation of surface chemistries of the three types of MSNs used in the
study. The bulky polyethylenimine (PEI) group in PEG-PEI-coated MSNs (i) is exposed
beyond the PEG layer, unlike the smaller quaternary amine (QA) and trimethylsilane
(TMS) groups in PEG-QA- (ii) and PEG-TMS- (iii) coated MSNs, respectively, which
remain obstructed by PEG molecules. PEI and QA groups provide a strongly positive zeta
potential (ζ) to MSNs, while TMS makes them neutral. b, Table shows details of MSN
characterization (size, *PdI: polydispersity index, and ζ). Each MSN is identified by the
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type of surface coating (PEI, QA, or TMS) and nominal diameter (25, 50, 90, or 150) in
nm. Data represents mean ± SD, n = 3. Hydrodynamic stability of MSNs over time is shown
in Figure S 1. c, Representative TEM images of all MSNs used in the study. Scale bars,
100 nm. d, Regions of interest (ROIs) generated using inviCRO’s Multi Atlas
Segmentation Tool to perform quantification of whole-body radioactivity concentration. e,
A schematic of the underlying modeling hypothesis depicts an organ 𝐢 that receives influx
of NPs from its major feeding artery, and after passing through the vasculature of organ 𝐢,
NPs exit into venous blood. Assuming the influx and efflux processes to both follow first
order kinetics with rate constants 𝒌𝒊𝒏,𝒊 and 𝒌𝒐𝒖𝒕,𝒊 , respectively, we obtain a biexponential
function (equation (1)) to describe the concentration-time course of NPs in individual ROIs.
f, A schematic of the whole-body framework to understand the disposition of NPs. I.p.
administration, unlike i.v. injection, is associated with absorption of NPs from the
peritoneal cavity into systemic circulation through bowel lymphatics, causing accumulation
of NPs in thoracic lymph nodes. Once in the systemic circulation through either route of
injection, NPs are distributed across all organs in the body in proportionality to organ blood
flow rates. Once inside the organ microvasculature, NPs encounter mechanisms (referred
to here as ‘traps’) like fenestrations, endothelial cells, and phagocytes that sequester NPs
form circulation, either into cells or into the interstitial space. Based on the low or high
density of traps in an organ, we can classify the organs as ‘source-like’ and ‘sink-like’,
respectively. Source-like organs do not sequester NPs due to a lack of traps; in contrast,
generally the sink-like organs entrap NPs because of being enriched with traps, unless
the physicochemical properties of NPs are unfavorable for entrapment. By allowing NPs
to pass through their vasculature without sequestration, source-like organs thus become
a secondary source of NPs for the sink-like organs (as depicted through the dotted black
arrow), which eventually dispose of the particles through excretory and metabolic
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pathways. Generally, source-like organs will have a higher 𝒌𝒐𝒖𝒕,𝒊 than sink-like organs,
due to lesser sequestration of NPs in the former.
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SPECT/CT imaging
Advancements in small-animal imaging techniques152 have enabled whole-body, threedimensional, dynamic imaging in rodents to quantify biodistribution of radiolabeled
xenobiotics in the presence of an anatomical reference. These techniques provide the
ability to study spatiotemporal evolution of whole-body biodistribution non-invasively within
the same animal, presenting a significant advantage over blood sampling and organ
resection. We injected cargo-less, gamma-ray emitting

111

In labeled MSNs i.v. or i.p. into

healthy female Fischer 344 rats, and conducted SPECT/CT imaging over 24 hours to
obtain the longitudinal biodistribution and clearance of MSNs. Reconstructed SPECT/CT
images were then quantified to obtain dose normalized radioactivity concentration of
MSNs (percent of injected dose per gram of tissue (% ID/g)) in ten ROIs (see Figure 3-1d,
Figure 3-2, Figure 3-3) (see Methods for details). The longer radioactive half-life of 111In (~2.8
days), over other commonly used SPECT radionuclides like 99mTc (half-life, ~6 hours) and
positron emission tomography (PET) radionuclides, makes

111

In-based SPECT ideal for

biodistribution studies spread over longer time periods. 157

Semi-mechanistic mathematical modeling
Different from our prior work on modeling free drug120,158-162 and targeted nanocarrier
delivery to tumors129,163,164, we here used a parsimonious, semi-mechanistic model to
describe the macroscopic concentration-time behavior of MSNs in individual ‘black boxlike’ ROIs and estimate relevant PK parameters. NPs traversing the organ
microvasculature encounter three critical microscopic mechanisms that work to remove
NPs from circulation: i) opsonization by plasma proteins165 which label the NPs as foreign
invaders for targeted phagocytosis166, ii) binding of NPs to vascular endothelial surfaces,
which may lead to cellular internalization167, and iii) fenestrated capillaries and sinusoids
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allowing extravasation2 of NPs into tissue interstitia or directing excretion168. These
microscopic mechanisms, referred to here as NP ‘traps’, are not distributed uniformly
across the body, but rather are localized in higher densities in the MPS organs, and thus
drive the macroscopic disposition profile of NPs. Our model is based on the hypothesis
that superposition of two opposing first order processes of influx and efflux of NPs, through
the vasculature of an ROI, can explain the observed concentration-time course of NPs in
the given ROI (see Figure 3-1e). The resulting integro-differential equation, similar to the
Bateman function34 for oral absorption of free drugs, governing the concentration 𝐶 (units,
% ID/g) of MSNs in individual ROIs is (see Methods in SI for details):
𝐶 (𝑡) = 𝐴 ∙ (𝑒
where 𝐴 =

,

,
,

∙

−𝑒

∙
,

,

∙

(1)

)

, is a macro-constant representing the intercept of back-extrapolated

elimination phase of biexponential concentration-time curve of an ROI, 𝑘

,

and 𝑘

,

are

the first-order uptake and elimination rate constants, respectively (units, h-1), and 𝐶 is the
concentration of NPs in arterial blood at 𝑡 = 0. Based on our data and the premise that a
differential density of traps exists across the body, ROIs can be classified as i) source-like
and ii) sink-like, where source-like ROIs tend not to sequester NPs into their interstitial
space, whereas sink-like ROIs tend to accumulate NPs in the interstitium (see Figure 3-1f
and Methods for details). The generalized equation (1) is thus adapted for the two classes
of ROIs to fit the concentration-time profile of MSNs and thus quantify in vivo disposition
(see Methods for details on modifications of equation (1)). To test equation (1) and its
modifications, we perform nonlinear regression of the model to concentration-time data of
individual ROIs.
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3.4. Results and Discussion
Generalized biodistribution of MSNs
From the representative SPECT/CT images in Figure 3-2 and their quantification in Figure
3-3, we can understand the generalized biodistribution behavior of MSNs and thus infer
similarities and differences between groups. As seen following i.v. injection in Figure 3-2ac, Figure 3-2g-i, and Figure 3-3a at the 30-minute time point, an almost identical
concentration is observed across all groups in the thoracic region (heart and lungs). The
exception however is PEI50 (Figure 3-2i and Figure 3-3a-v), where a much weaker signal is
observed in the thorax. As confirmed through one-way ANOVA and Tukey’s test on the
quantified concentration-time data of heart (Figure 3-3a), a significant difference is not
observed between groups at 30 minutes (P > 0.05), except with PEI50. Over time,
however, the concentration in the thorax tends to decline at different rates, suggesting that
the organs in the thorax tend not to accumulate MSNs into their interstitium, and NPs are
cleared from the blood pool of thoracic organs in a particle-type dependent fashion. This
justifies the classification of heart and lungs as source-like organs. In contrast, the
concentration in the abdomen (spleen and liver) tends to rise to a maximum followed by a
slow or zero decline within 24 hours post injection; note that this behavior is also particletype dependent (see Figure 3-2a-c, Figure 3-2g-i, and Figure 3-3a). The rise of MSN
concentration in MPS organs up to prolonged periods of time suggests that MSNs tend to
accumulate over time in the interstitium of these organs, hence a very small wash-out is
observed within 24 hours, justifying these organs to be classified as sink-like organs. The
literature shows that over time the spleen and liver gradually clear of the MSN load through
hepatobiliary route of elimination and not recirculation into blood26,147,148,169. Further, PEI50
MSNs (Figure 3-2i and Figure 3-3a-v) that exhibit the lowest concentration in heart and lungs
at 30 minutes among all groups, accordingly exhibit the highest accumulation in liver and
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spleen at 30 minutes, indicating a rapid hepatic and splenic uptake of PEI50 MSNs from
blood. As seen in Figure 3-2a-c, Figure 3-2g-i, and Figure 3-3a, the behavior of kidneys and
urinary bladder appears to be consistent across groups, except for QA50 (Figure 3-2h and
Figure 3-3a-vi), where the bladder shows significantly larger cumulative amounts over time
than other groups. Also, in Figure 3-2h QA50 shows radioactivity in the large intestine at
the 5h and 24 h time points, unlike other MSNs. Thus, because of the greater urinary and
fecal excretion, QA50 shows one of the lowest accumulations in spleen and liver among
other MSNs (see Figure 3-3a). Finally, other ROIs, including abdominal aorta, brain, joints,
and muscles exhibit only trivial concentrations (< 1.5% ID/g) across groups. Their
behavior, except joints, resembles that of source-like ROIs, i.e., a particle-type dependent,
exponential decline in concentration over time (see Figure 3-3a, Figure S 8a,b, Figure S 9a,b,
Figure S 10a,b,and Figure S 11a,b).
Next, as seen in Figure 3-2d-f, i.p. injection of PEG-TMS coated MSNs shows a
punctate biodistribution pattern throughout the abdomen at the initial time point of 30
minutes that maps the abdominal lymph circulatory network170, with mediastinal lymph
nodes in thorax (see ROI map Figure 3-1d) being an important site of radioactivity. This
initial phase represents the absorption of MSNs from the peritoneal cavity into blood 170,171.
Over time, however the distribution pattern starts to resemble that of the corresponding
i.v. cases for the three particle-types (Figure 3-2a-c), meaning that the MSNs have entered
the systemic circulation. This behavior demonstrates the in vivo stability of the MSNs with
respect to non-specific binding in lymph nodes. Having entered the circulatory system,
i.p.-injected MSNs ultimately exhibit a mass transfer phenomenon similar to the one
following i.v. administration, namely transfer of MSNs over time from source-like organs
(e.g., heart and lungs) to sink-like organs (e.g., liver and spleen), and finally excretion (as
depicted in Figure 3-1f). The kinetics of these processes are however particle-type
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dependent and in the subsequent sections we will unravel the effects of MSN
physicochemical properties on the kinetics of MSN disposition in blood, visceral organs,
and excretion.
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Figure 3-2: Representative SPECT/CT images (heat maps) demonstrating the
spatiotemporal evolution of whole-body biodistribution of MSNs.

PEG-TMS coated MSNs of nominal sizes 25 nm (a, d), 50 nm (b, e), 90 nm (Figure S 2),
and 150 nm (c, f) were injected via. i.v. (a-c, Figure S 2) or i.p. (d-f) route to understand the
effect of MSN size and route of administration. PEG-PEI- and PEG-QA-coated MSNs,
namely, QA50 (h) and PEI50 (i), were administered i.v. to explore the effect of surface
chemistry. Note that (b) and (g) are identical (shown here just for easy comparisons). Also,
TMS50 (b) and QA50 (h) were compared to understand the effect of zeta potential on
disposition of MSNs. Injections were followed by SPECT/CT imaging at 30 min, 5 h (6 h
in case of TMS150 (i.v.)), and 24 h. All SPECT images were scaled from 0.5-12% ID/g.
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Note: TMS90 MSN was not injected i.p.; lymph nodes and abdominal aorta were not
analyzed as ROIs in the i.v. and i.p. cases, respectively.
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Figure 3-3: Whole-body quantitative biodistribution of MSNs.
Bar plots of mean concentration-time data for various ROIs following a, i.v. and b, i.p.
injection of MSNs. For each MSN-type, concentration (% ID/g) of MSNs in ten ROIs is
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shown at 30 min, 5h (6h for TMS 150 (i.v.)), and 24 h, represented by three adjacent bars
of same color (see inset in a). Data represents mean ± SD, n = 4 (except TMS50 (i.p.) and
TMS25 (i.p.), where n = 3). Note: Data for urinary bladder ROI is presented as cumulative
amount (Σ% ID) and not as concentration.
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Systemic kinetics
We employed the SPECT-derived radioactivity concentration-time data of the heart ROI
as a substitute for plasma concentration-time data25,172,173 (assuming that MSNs in the
heart were in circulation) to understand systemic kinetics of MSNs and estimate relevant
PK parameters; see Figure 3-3 and Figure 3-4a,b. Since the concentrations of different
MSNs seems to vary in mono- or bi-exponential fashion, we fit a one-compartment PK
model10 (a monoexponential equation (S5) for i.v. and a biexponential equation (1) for i.p.)
to the concentration-time data. As seen in Figure 3-4a,b, nonlinear regression of the onecompartment PK model produced best fits with R2 > 0.93 (see Table S 2). Fitted
concentration-time curves demonstrate the effect of MSN size and route of administration
(Figure 3-4a) and surface chemistry and zeta potential (Figure 3-4b) on systemic kinetics of
MSNs. In Figure S 3, normalizing the predicted concentration over time (𝐶(𝑡)) of individual
MSNs by their own predicted concentration maxima (𝐶

) allows a direct comparison of

different groups. We then estimated area under the curves (𝐴𝑈𝐶
elimination rate constants (𝑘

and 𝑘

), and half-lives (𝑡

/

), uptake and

) of individual curves from

Figure 3-4a,b.
As seen in Figure 3-4c, 𝐴𝑈𝐶

decreases monotonically with an increase in particle

size in the studied size range of ~32 nm to ~142 nm, irrespective of the route of delivery,
governed by the mathematical relation: 𝐴𝑈𝐶

= 𝜆 ∙ 𝑠𝑖𝑧𝑒

, where 𝜆 is a numerical

coefficient (see Figure S 13e). Further, the elimination rate constant (𝑘
thus 𝑡

/

) increases (and

decreases) with an increase in size (see Figure 3-4e,f); however, one-way ANOVA

reveals no significant difference in the uptake rate constant (𝑘 ) values across i.p.
administered cases (P > 0.05) (see Figure 3-4d). This suggests that absorption of NPs from
peritoneal cavity in the studied size range is independent of particle size174 and that the
systemic bioavailability through either route of administration is primarily a function of the
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Figure 3-4: Systemic kinetics.
a,b, One compartment PK model (equation (S5) for i.v. and equation (1) for i.p.) was fit to
the concentration-time data for different MSNs in the heart ROI (R2 > 0.93 (Table S 2)).
Fitted concentration-time curves demonstrate the effect of MSN size and route of
administration for TMS-modified MSNs (a) and surface chemistry and zeta potential for 50
nm diameter MSNs modified with TMS, QA, or PEI (b). The inset in (a) is a rescaled
version of the figure for a clearer view. Solid lines, i.v. cases; dotted lines, i.p. cases. c-e,
3-D stem plots show area under the concentration-time curves (𝐴𝑈𝐶

) (c) and model

parameter estimates ((d) uptake rate constant, 𝑘 , and (e) elimination rate constant, 𝑘

),

obtained for different MSNs from a,b, in multiparameter space. f, Table shows values of
estimated half-lives (𝑡

/

) for different MSNs. Data represents mean ± SD, n = 4 (except

TMS50 (i.p.) and TMS25 (i.p.), where n = 3). Note: for TMS25 (i.p.), 𝑡

/

is not available

because an elimination phase was absent in its concentration-time profile within the
timeframe of study (see dotted black curve in a).
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𝑘

parameter. Published hemodynamic studies175-177 show that smaller particles tend to

have smaller margination175 probabilities in blood capillaries, in addition to being shielded
by erythrocytes, thus escaping near-wall accumulation, resulting in reduced extravasation
through fenestrations and reduced internalization by endothelium or near-wall
phagocytes178. Thus, greater protection from the traps in microvasculature yields a higher
systemic bioavailability for smaller sized particles.
The absolute bioavailability10 (ratio of dose normalized 𝐴𝑈𝐶

of i.p. to 𝐴𝑈𝐶

of i.v.) of i.p. administered TMS25, TMS50, and TMS150 MSNs is 72.8%, 66.6%, and
79.6%, respectively, assuming that the i.v. injected MSNs are 100% bioavailable. This
parameter quantifies the incomplete absorption of MSNs from the peritoneal cavity into
blood. It is however important to note that 𝑡

/

is not significantly different (P > 0.05)

between corresponding MSNs injected through the i.v. and i.p. route (see Figure 3-4f),
indicating that upon entering the blood stream MSNs behave independent of their route of
administration, which again highlights their in vivo stability necessary for clinical
translation.
Next looking at the effect of surface chemistry in Figure 3-4b,c,e,f, PEI50 with surface
exposed amines has a ~nine-fold lesser 𝐴𝑈𝐶

(P < 0.0001) and half the 𝑡

/

(P < 0.05)

of size- and zeta potential-matched QA50 with obstructed surface amines. These results
are consistent with our previously published report151, where we demonstrated the
difference in cellular and tissue interactions of PEG-PEI and PEG-QA coated MSNs in
vitro and ex ovo in the highly vascularized chicken chorioallantoic membrane model which
recapitulates the diverging-converging capillary vasculature associated with sink organs
like liver and spleen. It was shown that PEI50 rapidly binds to serum proteins and
endothelial cells in comparison to QA50. The subtle difference in surface chemistry
arguably alters the vulnerability of PEI50 MSNs to phagocytosis because of increased
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opsonization and hence reduced systemic residence, and is consistent with previous
studies of the effects of surface chemistry on protein corona179,180.
Interestingly, we observed no significant effect of zeta potential on the 𝐴𝑈𝐶

of

size- and surface chemistry-matched, but differently charged TMS50 and QA50 particles
(P > 0.05) (see Figure 3-4c), although the positively charged QA50 has a slightly lesser
𝑘

(hence slightly greater 𝑡

/

) than neutral TMS50 (P < 0.05) (see Figure 3-4e,f). As seen

before in Figure 3-2b,h, the washout of TMS50 from thorax is accompanied by increased
concentration of MSNs in the liver and spleen, but that of QA50 is accompanied primarily
by excretion into large intestine and urinary bladder. This indicates that the positively
charged particles tend to be excreted out faster than their neutral counterparts, which tend
to be sequestered in liver and spleen longer147, but without much difference in the systemic
exposure of the two particles.

Individual-organ kinetics
As described before, we theoretically classify ROIs in the body as source-like and sinklike, which becomes more evident as we consider the kinetic behavior of MSNs in
individual ROIs. Because of source-like ROIs, namely lungs, abdominal aorta, muscles,
and brain, being deficient in traps, MSNs do not sequester into their interstitium, rather
only traverse through the blood pool of these ROIs. Hence a monoexponential decay
function (equation (S5)) explains the concentration-time course of MSNs through such
ROIs, producing best fits with R2 > 0.89, except PEI50 (i.v.) in lungs and brain (see Figure
3-5a,d, Figure S 8a,b, Figure S 9a,b, Figure S 10a,b, and Table S 2). MSNs demonstrate
synchronous behavior across all source-like ROIs, which in turn closely resembles their
behavior to the heart ROI (substitute for plasma) (Figure 3-4a,b). A change in the heart
concentration of MSNs is reflected by a similar change in source-like ROIs, as is also
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evident from similarity in the 𝑘

values of MSNs across ROIs (ANOVA, P > 0.05, except

PEI50 (P = 0.03) (comparing Figure 3-4e, Figure S 4c, Figure S 8f, Figure S 9g, and Figure S
10g). This is strongly suggestive of a coupling between the heart and source-like ROIs;
heuristically, the underlying reason lies in the similar microanatomy of these ROIs. As
seen in the ROI-to-heart concentration ratios (Figure 3-5g, Figure S 8c, Figure S 9c, and Figure
S 10c), source-like ROIs have an almost constant ratio over time, which corroborates the
coupling of source-like ROIs to the heart. Also, the mathematical relation 𝐴𝑈𝐶
𝑠𝑖𝑧𝑒

=𝜆∙

holds true for all source-like ROIs as well (Figure S 13a,b,c,f). All the above suggest

that the effect of MSN physicochemical properties and routes of administration on MSN
disposition kinetics in source-like ROIs is similar to that on systemic kinetics. The
concentration levels however do vary across ROIs because of differences in organ
perfusion (see Figure 3-3).
As anticipated, the sink-like ROIs (i.e., liver, spleen, and thoracic lymph nodes) behave
differently than the heart and source-like ROIs. MSN concentrations in these ROIs rise
over time followed by slow or no decline in concentration within 24 hours, indicating the
presence of traps causing MSN accumulation over time into the interstitium or into resident
macrophages (see Figure 3-5b,c,e,f and Figure S 7a). As a result in Figure 3-5b,c,e,f and
Figure S 7a equation (1) or its adaptation, equation (S4), is fit to MSN concentration-time
data in sink-like ROIs, with R2 > 0.81, except TMS50 (i.p.) in spleen (see Table S 2)).
As to the effect of MSN size, a larger size of TMS-coated MSNs is associated with a
greater 𝐴𝑈𝐶

in sink-like ROIs, irrespective of route of administration, indicating a

greater organ exposure to MSNs (see Figure 3-5k,l and Figure S 7d). The mathematical
relations between 𝐴𝑈𝐶

and particle size (~32 ≥ size ≤ ~142), 𝐴𝑈𝐶

i.v.) and 𝐴𝑈𝐶

.

= 𝜆 ∙ 𝑠𝑖𝑧𝑒

= 𝜆 ∙ 𝑠𝑖𝑧𝑒 (for

(for i.p.), are consistent across all sink-like ROIs (see Figure

S 13d,g,h). Comparing the effect of route of administration, i.v. delivered TMS- coated
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Figure 3-5: Organ kinetics.
Panel shows kinetic analysis for lungs, liver, and spleen. For analysis of the remaining
ROIs refer to Figure S 7, Figure S 8, Figure S 9, Figure S 10, and Figure S 11. a-f, For each ROI,
nonlinear regression of equation (1) or its adaptations was performed on the
concentration-time data (R2 > 0.81, except PEI50 (i.v.) in lungs and TMS50 (i.p.) in spleen
(Table S 2)). Solid lines, i.v. cases; dotted lines, i.p. cases. The inset in (a) is a rescaled
version of the figure for a clearer view. g-i, Observed concentration of ROIs normalized to
concentration of heart (substitute for plasma) is shown over time on a log-log plot. j-l, 3-D
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stem plots show area under the concentration-time curves (𝐴𝑈𝐶

), obtained for

different MSNs from a-g, in multiparameter space. Data in all plots represents mean ± SD,
n = 4 (except TMS50 (i.p.) and TMS25 (i.p.), where n = 3).
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MSNs are associated with a higher 𝐴𝑈𝐶

value than their i.p. delivered

counterparts in spleen (P < 0.05), but with comparable values in liver (P > 0.05) (see Figure
3-5k,l).
For the PEI50 MSNs with surface exposed amines, spleen and liver are the prime sites
of radioactivity, unlike the size- and zeta potential-matched counterpart, QA50, with
obstructed amines (see Figure 3-3a and Figure 3-5e,f). QA50 however shows resemblance
in its behavior to TMS50, indicating that surface chemistry plays a bigger role in affecting
the hepatic and splenic accumulation of MSNs compared to zeta potential. It is worth
mentioning that TMS25 (i.v.) and QA50 (i.v.), show deviation from the norm in liver and
show a decline in concentration over time; hence, the monoexponential decline equation
(S5) was fit instead (R2 > 0.81) to their concentration-time course (Figure 3-5b,e). This is
also evident from the almost constant liver-to-heart concentration ratio for the two MSNs,
unlike other MSNs with growing ratio over time (Figure 3-5h). Small size of TMS25 seems
unfavorable for MSN sequestration in liver144 and the positive zeta potential of QA50
seems favorable for hepatobiliary elimination147, hence overall a low sequestration in liver
is observed leading to an almost constant liver-to-heart concentration ratio. This
information is valuable for MSN design optimization.

Excretion kinetics
Urine and feces were not collected during the in vivo study; we thus examine kidneys,
urinary bladder, and whole-body ROIs (Figure 3-6a-f) to understand the excretion kinetics
of MSNs. A monoexponential decay function (equation (S5)) was fit to the concentrationtime data in the kidneys following i.v. injection, and equation (1) was fit following i.p.
injection. As seen in Figure 3-6a,d, there is a tight overlap between the kidney
concentration-time profiles of various MSNs injected i.v. or i.p., with a mean radioactivity
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concentration of < 2.5 % ID/g at 30 minutes in all cases, and an overall trend of decline in
concentration over time. Because we do not observe a relation between the particle
physicochemical properties and behavior in kidneys, and the radioactivity from kidneys
may be a result of MSNs in the pre-glomerular vasculature, we refer to the urinary bladder
ROI for an understanding of renal clearance of MSNs. Looking at the nonlinear regression
of equation (S6) to cumulative amount-time data of various MSNs in urinary bladder (Figure
3-6b,e), we observe that the positively charged, QA50 has a greater total amount excreted
via urine than other MSNs, consistent with evidence in literature142 (ANOVA, P < 0.0001)
(see Table S 2). TMS-coated MSNs of different sizes injected i.v. or i.p. are excreted to a
comparable amount (except TMS25 (i.v.), which has the least amount excreted),
consistent with prior studies showing that degradation products of larger MSNs appear in
urine faster than smaller MSNs144. Thus, we do not identify a correlation between size or
route of administration and urinary excretion.
We fit equation (S6) to the total excreted activity (% ID) over time (Figure 3-6c,f),
obtained by subtracting the whole-body activity (% ID) from 100%. The total excreted
activity includes excretion by both urinary and fecal routes. The data demonstrates that
the total excretion behavior correlates with the cumulative amount behavior in the urinary
bladder (Figure 3-6b,e).
Appearance of radioactivity in the urinary bladder defies the established paradigm that
solid particles > ~5.5 nm in diameter cannot be efficiently cleared through kidneys 4.
However, previous studies have demonstrated the appearance of intact silica NPs as large
as

110

nm

in

urine,

without

any

apparent

damage

to

the

glomerular

microarchitecture148,181,182. Biochemical indicators of biliary and glomerular function were
altered by treatment with MSNs, suggesting that biliary and glomerular function may have
been dysregulated, and could help explain the intact excretion of particles without obvious
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Figure 3-6: Excretion kinetics.
Urine and feces were not collected during the in vivo study, we thus examine the kidneys,
urinary bladder, and whole-body ROIs to infer excretion kinetics of MSNs. a,d, ROI
concentration-time data of kidneys was fit to equation (S5) for i.v. cases and equation (1)
for i.p. cases. b,c,e,f, To the cumulative urinary bladder and cumulative complement of
whole-body (100 – whole-body) ROI data, equation (S6) was fit to all cases. (R2 > 0.91,
except TMS150 (i.v.) in kidneys (Table S 2)). The insets in (a, b, d, e) are a rescaled version
of their corresponding figures for a clearer view. Solid lines, i.v. cases; dotted lines, i.p.
cases.

Cumulative amount, instead of concentration, was used as the measure of

excretion. Data represents mean ± SD, n = 4 (except TMS50 (i.p.) and TMS25 (i.p.), where
n = 3).
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damage181.
The onset of clearance from animal models appears to be less than 30 minutes with
positively charged particles, and longer (up to several days) with strongly negatively
charged particles147. This observation is consistent with our study, which shows that
strongly positively charged particles, QA50, show higher clearance. However, the other
highly positively charged PEI50 shows lesser renal clearance than QA50 because of its
greater accumulation in the liver and spleen (see Table S 2).
While it is known that MSNs can be broken down into nontoxic silicic acid species, the
particles can also be excreted intact or only partially broken down. TEM analysis of urine
of mice i.v. injected with PEG-TMS MSNs showed intact MSNs in the urine (see Figure S
14). While few studies have examined the urine for the presence of particles, the ability of
the particles to clear in this manner, potentially without damage, could explain the very
rapid appearance of signal in the bladder in both our study and in previous studies, which
suggest clearance begins as early as 30 minutes post injection147. The rapid onset of
clearance and the potential for intact particle clearance should be investigated further in
future experiments. The safety of MSNs is supported by the fact that amorphous silica is
Generally Recognized as Safe (GRAS) by the FDA and recently amorphous silica NP ‘Cdots’ (Cornell Dots) were FDA approved for diagnostic applications in a stage I human
clinical trial183.

3.5. Conclusions
We have demonstrated the application of a combined mathematical modeling and
non-invasive SPECT/CT imaging approach to PK analysis of MSNs. The range of the
particles used to test the effect of size, charge, and surface chemistry reveals that in vivo
biodistribution and clearance of NPs is significantly affected by these physiochemical
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properties. We justified the classification of ROIs into source-like and sink-like organs
based on their underlying physiological differences and observed NP kinetics, and applied
semi-mechanistic models to the concentration-time profiles of NPs in these ROIs to
determine relevant PK parameters. Our analysis showed that smaller size corresponds
with higher systemic bioavailability, irrespective of route of delivery; positive charge favors
greater excretion; and importantly surface exposed charged molecules (amines) increase
vulnerability to sequestration in liver and spleen. Notably, a consistent mathematical
relation between one key PK parameter (𝐴𝑈𝐶
of 𝐴𝑈𝐶

= 𝜆 ∙ 𝑠𝑖𝑧𝑒

) and NP size was identified in the form

for systemic circulation and all source-like organs in both i.v. and

i.p. cases; however, for sink-like organs, two such relations were identified, i.e.,
𝐴𝑈𝐶

= 𝜆 ∙ 𝑠𝑖𝑧𝑒 and 𝐴𝑈𝐶

= 𝜆 ∙ 𝑠𝑖𝑧𝑒

.

, for i.v. and i.p. cases, respectively.

Regarding the predictive power of our semi-mechanistic mathematical model, it
operates at a macroscopic scale, i.e. is based on the organ- or tissue-scale concentrationtime profiles of NPs, which means that several microscopic mechanisms are lumped into
the phenomenological macroscopic constants and variables in the model. The predictive
capacity of the model is thus limited in scale. The model can help predict organ exposure
of MSNs based on functional relationships (see above) between organ exposure
(𝐴𝑈𝐶

) and MSN size through interpolation within the size range of the study (~32 nm

to ~142 nm). As for extrapolation beyond the studied size range, we expect its accuracy
to worsen for NP size below 5.5 nm. Because of predominance of renal clearance below
5.5 nm, systemic circulation and exposure of source-like and sink-like organs to such
particles will be drastically reduced, which means that the correlation function for at least
systemic circulation and source-like organs, if not for sink-like organs, will be reversed as
per a published report.4 Thus, we would like to assume 5.5 nm as the safe lower bound
for the functions defined in our study. For sizes above 142 nm, we expect the functional
relationship discovered here to apply, as larger sizes of NPs should continue to correlate
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with even greater hepatic and splenic uptakes184. Further, as for relationship between
𝐴𝑈𝐶

and zeta potential, we find no significant effect of zeta potential on the systemic

circulation and source-like organ exposure of MSNs. However, positive charge correlates
with greater hepatobiliary excretion, hence lower liver accumulation compared to neutral
MSNs. Similarly, we observed greater urinary excretion of cationic MSNs over neutral
MSNs, which makes sense given the presence of anionic charge within the glomerular
capillary wall142. Based on these trends, we can thus extrapolate that anionic MSNs will
have reduced hepatobiliary and urinary excretion.147,169 Furthermore, based on the scope
of our study, we propose TMS25 and QA50 as the choice of MSNs for therapeutic
applications, primarily due to their low hepatic and splenic clearance. Because TMS25
stays in circulation ~four times longer than QA50, in applications demanding longer
circulation times, e.g. tumor delivery, the neutral TMS25 MSN appears to be a better
choice over the positive QA50.
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3.6. Supplementary Information
Methods Overview
To study the effect of particle size, PEG-TMS-coated MSNs of four different nominal sizes
(25 nm, 50 nm, 90 nm, and 150 nm) were administered i.v., and three different nominal
sizes (25 nm, 50 nm, and 150 nm) were administered i.p. The i.v. and i.p. groups were
also compared to investigate the effect of route of administration. To study the effect of
zeta potential, size- and surface chemistry-matched MSNs (TMS50 and QA50) were
compared. Here, surface chemistry refers to the spatial arrangement and relative
exposure of surface amines (depicted in Figure 3-1a), rather than the chemical identity of
surface ligands. To study the effect of surface chemistry, size- and zeta potential-matched
particles (QA50 and PEI50) were analyzed. Bolus tail vein or i.p. injection of particles
conjugated with radioactive Indium-111 (111In) was given to healthy female rats, followed
by whole-body SPECT/CT imaging of animals longitudinally over 24 hours. Regions of
interest (Figure 3-1d) analysis was performed on reconstructed SPECT/CT images to
obtain dose normalized radioactivity concentration time-course data. Semi-mechanistic
modeling and pharmacokinetic (PK) analysis were then performed to understand the effect
of physicochemical properties and routes of administration on MSN disposition kinetics.

Nanoparticle synthesis and characterization
The synthesis of colloidally stable PEGylated MSNs with various sizes and different
surface chemistries was based on published methods151,156,185. To enable detection by
SPECT, monodisperse MSNs were covalently-coupled to diethylene triamine pentaacetic
acid (DTPA) through isothiocyanate and amine reactions to enable binding of

111

In, a

gamma emitting radioisotope with a radioactive half-life of 2.8 days157. First, 7.5 mg of S2-(4-Isothiocyanatobenzyl)-diethylenetriamine
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pentaacetic

acid

(p-SCN-Bn-DTPA,

Macrocyclics, Pano, TX), 3.75 µL of 3-aminopropyltriethoxysilane (APTES, Sigma Aldrich,
St. Louis, MO), and 15 µL of trimethylamine (Sigma Aldrich, St. Louis, MO) were mixed in
1 mL of anhydrous ethanol under continuous agitation for 18 h. Then, 0.29 g of cationic
surfactant, n-cetyltrimethylammonium bromide (CTAB, Sigma Aldrich, St. Louis, MO) was
dissolved in 150 mL of ammonium hydroxide (NH4OH, Sigma Aldrich, St. Louis, MO)
solution and heated to 50oC. After 1 h, dilute tetraethyl orthosilicate (TEOS, Sigma Aldrich,
St. Louis, MO) solution (prepared in ethanol) and APTES/p-SCN-Bn-DTPA mixture
solution were added simultaneously to the CTAB containing ammonium hydroxide
solution. After an additional 1 h of continuous stirring, 2-methoxypolyethyleneoxypropyltrimethoxysilane (PEG-silane, Gelest, Morrisville, PA) was added to the solution
and the mixture was stirred for 30 min., then a secondary silane (trimethylchlorosilane,
TMS, Sigma Aldrich, St. Louis, MO or trimethoxysilylpropyl modified polyethyleneimine,
50% in isopropanol, MW 1500-1800, PEI-silane, Gelest, Morrisville, PA or Ntrimethoxysilylpropyl-N,N,N-trimethyl ammonium chloride, 50% in methanol, TMACsilane), was added. Stirring was stopped after an additional 30 min., and solution was
stored at 50oC for 20 h. Solutions were then sealed and stored at 90oC for 24 h for
hydrothermal treatment. Next, we followed a procedure for CTAB extraction described
previously in the literature186. Prior to use, MSNs were transferred to DI water at a
concentration of 10 mg/mL.
The detailed conditions and amounts of chemical reagents used in the preparation of
PEG-TMS, PEG-PEI, and PEG-QA modified MSNs are described in Table S 1.
To load 111In3+ to MSNs, InCl3 solution (Inidiclor, GE Healthcare, Arlington Heights, IL)
was incubated with the DTPA-modified PEG/TMS, PEG/PEI, or PEG/QA NPs, using 15
mCi of In-111 per 10 mg particles, for 30 min. at room temperature in 500 mM Sodium
Citrate Buffer. Unbound

111

In was removed by centrifugation at 21,000 x g for 60 min.,
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followed by resuspension in 1 mL of 1 x PBS at 10 mg/mL. No loss of radioactivity from
the MSNs was observed following 2 subsequent washes.
The purified PEGylated MSNs were characterized by transmission electron
microscopy (TEM), dynamic light scattering (DLS), and zeta potential prior in vivo
injections. TEM images were acquired with JEOL 2010 (200 kV voltage, Tokyo, Japan)
equipped with a Gatan Orius digital camera system (Warrendale, PA). Hydrodynamic size
and zeta potential analyses (Table S 1) were performed on a Malvern Zetasizer Nano-ZS
equipped with a He-Ne laser (633 nm) and Non-Invasive Backscatter optics (NIBS). All
samples for DLS or zeta potential measurements were suspended in either PBS or 10 mM
NaCl at 200 µg/mL. Measurements were acquired at 25oC in triplicate. The Z-average
diameter and number particle size distribution was used for all reported hydrodynamic size
measurements. The zeta potential for each sample was obtained from monomodal
analysis measurements. All reported values correspond to the average of at least three
independent samples.

Animal study design, SPECT/CT imaging, and quantification
All procedures involving rats were conducted in accordance with the National Institutes of
Health regulations concerning the care and use of experimental animals. This study was
approved by the University of New Mexico Health Sciences Center Institutional Animal
Care and Use Committee (protocol #13-101096-HSC) and the USAMRMC Animal Care
and Use Review Office (protocol #CB-2013-29.03).
Healthy female Fischer 344 rats (approx. 150 g each) were used in these studies.
Each rat was administered 1 mg of particles, suspended in 200 µL of 0.5x PBS and labeled
with approximately 1 mCi of 111In by either tail vein (i.v.) or i.p. injection. Four groups (N =
4 rats per group) were administered PEG-TMS-coated particles of different nominal sizes
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(25, 50, 90, or 150 nm) by tail vein injection. Two additional groups (N = 4 rats per group)
received 50 nm particles i.v. coated with PEG-PEI or PEG-QA, respectively. Further, three
additional groups were administered 1 mg of PEG-TMS particles of different nominal sizes
(25, 50, or 150 nm) by i.p. injection (N = 3 rats per group, except TMS150, where N = 4
rats per group).
SPECT/CT imaging was conducted at the Keck-UNM Small Animal Imaging Resource
using a dual-modality NanoSPECT/CT® Small Animal In Vivo Imager (Bioscan, Inc.,
Washington, D.C.). For each subject, the 111In biodistribution was imaged longitudinally at
three-time points (30 min., 5 h (6 h instead for TMS150 (i.v.) group), and 24 h), postinjection with the rat maintained under isoflurane anesthesia on a heated bed (37°C)
during imaging. The CT acquisition (approx. 5 min. duration) was completed using 180
projections with a pitch of 1.5. Helical SPECT acquisition included 32 projections and
varying time per projection resulting in an acquisition time of 15-30 min. per time point.
Immediately after the 24 h imaging time point, each rat was euthanized and tissues were
harvested and fixed in 10% formaldehyde for future analysis by microscopy.
The SPECT/CT image data were exported to VivoQuant 2.00 software (inviCRO, LLC,
Boston, MA) for image reconstruction, display, and analysis. Camera calibration and
reconstructions were performed using both In-111 gamma energy windows (0.1713 and
0.2454 MeV). Co-registered CT and SPECT axial images were reconstructed with a 176
x 176 matrix, 0.4 mm in-plane resolution, and a slice thickness of 0.4 mm. The number of
slices for each whole-body image was approximately 450. Tissue segmentation and ROI
analysis were performed by inviCRO, LLC. ROIs corresponding to the whole body, brain,
liver, kidneys, spleen, heart, lungs, lymph nodes, bladder, abdominal aorta, bone (knee
joint), and muscles (Figure 3-1d) were selected according to the following procedure:
except for muscle and bone ROIs, which were generated manually, ROIs were generated
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using inviCRO’s Multi Atlas Segmentation Tool. First, fixed volume ROIs were placed
manually for 10 CTs, and used as a reference library for 10 additional scans. The final
reference library included all 20 CTs. The reference CTs were registered to each new data
set using both affine and deformable registration. The reference ROI had the same
transform applied to it, resulting in 20 representations of possible ROI locations. Finally,
using the best 5 registrations, a probability map of each ROI was created and thresholded
to generate a final ROI of the correct volume. At each time point, ROIs were quantitatively
analyzed to determine the dose normalized concentration of radiolabeled NPs (expressed
as percent of injected dose per gram tissue, % ID/g) based on the total activity detected
in the ROI, the ROI volume, and the tissue density.

Mathematical modeling and pharmacokinetic analysis
At the very outset, it is important to understand that the radioactivity observed in SPECT
images has two origins: 1) radioactivity from NPs circulating through the vasculature of
organs, and 2) radioactivity from NPs sequestered in the extravascular space of organs
(due to the activity of NP ‘traps’, discussed in introduction). The former NPs are still
bioavailable for delivery to a potential target site, but the latter are not unless the organ
they are sequestered in is the target organ. We propose that the extent of NP
sequestration in the extravascular space of an organ is dependent on the density of traps
in the organ’s microvasculature. We were able to classify the organs in the body according
to high or low density of the most relevant physiological traps (phagocytes, fenestrae,
interendothelial gaps)187,188. Large blood vessels (e.g. the aorta) as well as capillaries in
the muscles (including the heart), lungs, and brain have continuous endothelium, and thus
lack fenestrations large enough to allow NP escape from circulation6,189. Kidney glomerular
capillaries have fenestrations with a diameter of ~60 nm6,190, but with a physiological limit
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of ~5.5 nm4 for renal clearance. Spleen and liver have capillaries (sinusoids) with
discontinuous endothelium having pore sizes of ~5 µm and ~180 nm, respectively6,188,189.
Similarly, the neovasculature of tumors has marked inter-endothelial gaps ranging
between 200-2000 nm in diameter2, leading to the enhanced permeability and retention
(EPR) effect2. Furthermore, among the phagocytes of MPS organs, Kupffer cells of the
liver, macrophages of the spleen, and macrophages of the bone marrow have access to
circulating blood, and are thus considered the prime culprits in removing NPs from
circulation53,187,191,192. However, in other organs, such as the lungs, where the alveolar
macrophages exist on the air-side of the blood-air barrier, the contribution of phagocytes
in removing NPs from blood is negligible.
In a nutshell, ROIs that are ‘almost’ devoid of traps (aorta, heart, lungs, brain, muscles)
act as ‘source-like’ organs. We thus assume that the radioactivity from such ROIs is the
result of NPs traveling through the vasculature of these organs without getting
permanently trapped into the extravascular space31. They represent the blood pool
through which NPs travel without being taken up into the interstitium, remaining
bioavailable for delivery to the ‘sink’ organs, i.e. organs enriched in traps, including, liver,
spleen, kidneys, lymph nodes, and tumor (if any). In contrast, NPs in the ‘sink-like’ organs
can passively accumulate over time in the extravascular space, and may additionally be
metabolized/excreted, leading to a permanent loss of bioavailable NPs.
As shown in Figure 3-1e, an organ 𝑖 receives an influx of NPs from the major feeding
artery. Based on the characteristics of NPs and organ anatomy and physiology at the
microvascular scale, NPs traverse through the vasculature of organ 𝑖 while forming
transient or permanent associations with intravascular traps. The untrapped fraction of
incoming particles is free to leave organ 𝑖 and rejoin the venous blood. These interactions
at the microvascular scale thus govern the global biodistribution profile of NPs. Given the
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nature of data in the current study, we do not model NP interactions at microscopic scale,
but only phenomenologically describe the observed macroscopic concentration-time
behavior of NPs using a parsimonious model.
Assuming the influx and efflux process of NPs both follow a first order kinetics, we thus
obtain the following differential equation describing the rate of change of concentration 𝐶
(units, % ID/g) of NPs in organ 𝑖:
=𝑘
where 𝑘

∙𝐶

,

,

,

−𝑘

,

and 𝑘

,

(units, h-1); and 𝐶

(S1)

∙𝐶

are the first-order uptake and elimination rate constants, respectively
is the concentration of NPs in the local arterial blood supply of organ

,

𝑖, which changes at a rate assumed to be governed by a first order distribution process:
𝐶 , (𝑡) = 𝐶 ∙ 𝑒

,

∙

(S2)

where 𝐶 is the local systemic concentration of particles at 𝑡 = 0.
The integrated form of Eq. (S1), solved for initial condition 𝐶 (0) = 0 is:
𝐶 (𝑡) = 𝐴 ∙ (𝑒

,

∙

−𝑒

,

∙

(S3)

)

where the macro-constant 𝐴 =

,
,

∙
,

, is the intercept of back-extrapolated elimination

phase of biexponential concentration-time curve of an ROI. This equation resembles the
Bateman function34 for oral absorption of free drugs. Based on empirical evidence from
the quantified SPECT/CT images, equation (S3) was further adapted to model the
behavior of individual source-like and sink-like ROIs, under i.v. or i.p. conditions of MSN
administration.
Following i.p. delivery, for all source-organs and lymph nodes (sink-like organ), an
obvious uptake phase followed by an elimination phase is observed; thus, we fit equation
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(S3) in its canonical form to the concentration-time data. However, for the remaining sinklike organs following i.p. delivery, an apparent elimination phase was not seen within the
duration of study, thus assuming 𝑘
, ,∙

𝐶 (𝑡) = 𝐴 ∙ (1 − 𝑒

≅ 0, equation (S3) becomes:
(S4)

)

Further, fitting equation (S3) to the source-like organs in i.v. case, we found that 𝑘
𝑘

≫

, and as a result, the second exponential term in equation (S3) becomes insignificant,

reducing the equation for source-like ROIs to:
𝐶 (𝑡) = 𝐴 ∙ 𝑒

,

∙

(S5)

And, in the case of sink-like organs following i.v. injection, equation (S3) is employed to
model the empirical behavior of MSNs in liver, and equation (S4) in spleen, based on
whether elimination is seen in the data. For the activity observed in urinary bladder, we
use the cumulative amount (cumulative % ID), instead of concentration, of NPs to describe
the renal excretion behavior of NPs. Concentration is largely irrelevant in the context of
accumulation of NPs in bladder, because the volume of urine being produced will strongly
influence the concentration but not the amount of NPs being excreted. In the case of the
urinary bladder ROI for both i.v. and i.p. cases, we use an adaptation of equation (S4):
𝑈(𝑡) = 𝑈 ∙ (1 − 𝑒

∙

(S6)

)

where 𝑈 is the cumulative amount of MSNs in urinary bladder at time 𝑡 (units % ID); 𝑘 is
the first order urinary excretion rate constant (units h-1); and 𝑈 is the total amount of MSNs
excreted via urine.
To estimate model parameters and correlate them to the physiological and
physicochemical underpinnings of the observed in vivo behavior of MSNs, we performed
non-linear regression analyses of the semi-mechanistic models (equations (S3, S4, S5,
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and S6)) to concentration (or, cumulative amount)-time data of individual ROIs. Further,
we performed traditional PK analysis by employing the concentration-time data of the
heart ROI as a substitute for plasma concentration-time-course data. This substitution
assumes that radioactivity from the heart ROI is purely due to NPs in the blood pool of the
heart, and not in the extravascular tissue space (based on our previous discussion of the
heart being a source organ). Based on the nature of concentration-time curves of MSNs
in the heart, we applied a one-compartment PK model10 (same as equations (1 or S5) for
i.v. delivery, and equation (S3) for i.p. delivery), and determined PK parameters: i) area
under the curve from 0-24 hours (𝐴𝑈𝐶
rate constant (𝑘

), ii) uptake rate constant (𝑘 ), iii) elimination

), and iv) half-life (𝑡

/

). 𝐴𝑈𝐶

represents the systemic

bioavailability of NPs and is the definite integral of NP concentration-time in plasma (heart,
in this study), determined analytically. 𝑘
log plot between 𝐶
per unit time. 𝑡

/

/

and 𝑡, and represents the fraction of NPs eliminated from plasma

is the time required for NP concentration to reduce to half, and for a one-

compartment model, 𝑡
𝑡

is the slope of the terminal phase on a semi-

/

10,193

is obtained as:
(S7)

= ln(2) /𝑘

Further, we also estimated model parameters for all the other ROIs to understand the
effect of MSN characteristics and route of administration on organ exposure to MSNs, and
their uptake and elimination behaviors.

Statistical Analysis
For in vivo studies, four animals per group were used. One subject from the TMS25 (i.p.)
group and one subject from the TMS50 (i.p.) group were excluded from analysis due to
subject motion and a misplaced injection, respectively, resulting in N = 3 for these groups.
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Experimental results are presented as mean ± standard deviation (SD). One-way ANOVA
and Tukey’s honest significant difference procedures were performed to evaluate
differences in model parameters across groups. Unpaired-sample t-test was also
performed for relevant pairwise comparisons. The ‘Levenberg-Marquardt’ algorithm 194
was used to perform non-linear regression analysis to the observed data. All analyses
were performed in MATLAB R2015b195.
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Figure S 1: Hydrodynamic stability of MSNs.
Time-dependent stability of MSNs in 1x PBS at 25oC over a period of five to seven days.
Data represents mean ± SD, n = 3.
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Figure S 2: SPECT/CT imaging of TMS90 MSNs.
Representative SPECT/CT images of a rat injected intravenously with TMS90 MSNs.
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Figure S 3: Kinetics of heart.
Plot of predicted concentration (𝑪(𝒕)) normalized to predicted concentration maxima
(𝑪𝒎𝒂𝒙 ) of different MSNs in the heart.
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Figure S 4: Kinetics of lungs.
a, Plot of predicted concentration (𝑪(𝒕)) normalized to predicted concentration maxima
(𝑪𝒎𝒂𝒙 ) in the lungs. 3-D stem plots show b, uptake rate constants, 𝒌𝒊𝒏 (𝒉
elimination rate constants, 𝒌𝒐𝒖𝒕 (𝒉

𝟏

𝟏

), and c,

), for the lungs in multiparameter space. Refer to

Table S 2 for more details.
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Figure S 5: Kinetics of liver.
a, Plot of predicted concentration (𝑪(𝒕)) normalized to predicted concentration maxima
(𝑪𝒎𝒂𝒙 ) in the liver. 3-D stem plots show b, uptake rate constants, 𝒌𝒊𝒏 (𝒉
elimination rate constants, 𝒌𝒐𝒖𝒕 (𝒉

𝟏

𝟏

), and c,

), for the liver in multiparameter space. Refer to Table

S 2 for more details.
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Figure S 6: Kinetics of spleen.
a, Plot of predicted concentration (𝑪(𝒕)) normalized to predicted concentration maxima
(𝑪𝒎𝒂𝒙 ) in the spleen. 3-D stem plots show b, uptake rate constants, 𝒌𝒊𝒏 (𝒉
elimination rate constants, 𝒌𝒐𝒖𝒕 (𝒉

𝟏

𝟏

), and c,

), for the spleen in multiparameter space. Refer to

Table S 2 for more details.
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Figure S 7: Kinetics of thoracic lymph nodes.
a, Plot of nonlinear regression of equation (1) to the concentration-time data of MSNs in
thoracic lymph nodes. b, Observed concentration of thoracic lymph nodes normalized to
concentration of heart (substitute for plasma) is shown over time on a log-log plot. c, Plot
of predicted concentration (𝑪(𝒕)) normalized to predicted concentration maxima (𝑪𝒎𝒂𝒙) in
the thoracic lymph nodes. 3-D stem plots show d, area under the concentration-time
curve (𝑨𝑼𝑪𝟎
𝒌𝒐𝒖𝒕 (𝒉

𝟏

𝟐𝟒 𝒉 ),

e, uptake rate constants, 𝒌𝒊𝒏 (𝒉 𝟏 ), and f, elimination rate constants,

), for the thoracic lymph nodes in multiparameter space. Refer to Table S 2 for

more details.
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Figure S 8: Kinetics of abdominal aorta.
a,b, Plots of nonlinear regression of equation (S5) to the concentration-time data of MSNs
in abdominal aorta. Fitted concentration-time curves demonstrate the effect of MSN size
for TMS-modified MSNs (a) and surface chemistry and zeta potential for 50 nm diameter
MSNs modified with TMS, QA, or PEI (b). The inset in (a,b) is a rescaled version of the
figure for a clearer view. Note: Abdominal aorta was not analyzed as an ROI in the i.p.
injection cases. c, Observed concentration of abdominal aorta normalized to concentration
of heart (substitute for plasma) is shown over time on a log-log plot. d, Plot of predicted
concentration (𝑪(𝒕)) normalized to predicted concentration maxima (𝑪𝒎𝒂𝒙) in the
abdominal aorta. 3-D stem plots show e, area under the concentration-time curve
(𝑨𝑼𝑪𝟎

𝟐𝟒 𝒉 )

and f, elimination rate constants, 𝒌𝒐𝒖𝒕 (𝒉

𝟏

multiparameter space. Refer to Table S 2 for more details.

91

), for the abdominal aorta in

Figure S 9: Kinetics of muscles.
a,b, Plots of nonlinear regression of equations (S5 and 1) to the concentration-time data
of MSNs in muscles. Fitted concentration-time curves demonstrate the effect of MSN size
and route of administration for TMS-modified MSNs (a) and surface chemistry and zeta
potential for 50 nm diameter MSNs modified with TMS, QA, or PEI (b). The inset in (a,b)
is a rescaled version of the figure for a clearer view. Solid lines, i.v. cases (equation (S5));
dotted lines, i.p. cases (equation (1)). c, Observed concentration of muscles normalized
to concentration of heart (substitute for plasma) is shown over time on a log-log plot. d,
Plot of predicted concentration (𝑪(𝒕)) normalized to predicted concentration maxima
(𝑪𝒎𝒂𝒙 ) in the muscles. 3-D stem plots show e, area under the concentration-time curve
92

(𝑨𝑼𝑪𝟎
(𝒉

𝟏

𝟐𝟒 𝒉 )

f, uptake rate constants, 𝒌𝒊𝒏 (𝒉

𝟏

), and g, elimination rate constants, 𝒌𝒐𝒖𝒕

), for the muscles in multiparameter space. Refer to Table S 2 for more details.
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Figure S 10: Kinetics of brain.
a,b, Plots of nonlinear regression of equations (S5 and 1) to the concentration-time data
of MSNs in brain. Fitted concentration-time curves demonstrate the effect of MSN size
and route of administration for TMS-modified MSNs (a) and surface chemistry and zeta
potential for 50 nm diameter MSNs modified with TMS, QA, or PEI (b). The inset in (a,b)
is a rescaled version of the figure for a clearer view. Solid lines, i.v. cases (equation (S5));
dotted lines, i.p. cases (equation (1)). c, Observed concentration of brain normalized to
concentration of heart (substitute for plasma) is shown over time on a log-log plot. d, Plot
of predicted concentration (𝑪(𝒕)) normalized to predicted concentration maxima (𝑪𝒎𝒂𝒙) in
the brain. 3-D stem plots show e, area under the concentration-time curve (𝑨𝑼𝑪𝟎
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𝟐𝟒 𝒉 )

f, uptake rate constants, 𝒌𝒊𝒏 (𝒉

𝟏

), and g, elimination rate constants, 𝒌𝒐𝒖𝒕 (𝒉

brain in multiparameter space. Refer to Table S 2 for more details.
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𝟏

), for the

Figure S 11: Kinetics of joints.
a,b, Plots of nonlinear regression of equations (S4, S5, and 1) to the concentration-time
data of MSNs in joints. Fitted concentration-time curves demonstrate the effect of MSN
size and route of administration for TMS-modified MSNs (a) and surface chemistry and
zeta potential for 50 nm diameter MSNs modified with TMS, QA, or PEI (b). The inset in
(a,b) is a rescaled version of the figure for a clearer view. Solid lines, i.v. cases (equation
(S5) for TMS150, PEI50, and QA50, equation (1) for TMS50, and equation (S4) for TMS25
and TMS90); dotted lines, i.p. cases (equation (S4)). c, Observed concentration of joints
normalized to concentration of heart (substitute for plasma) is shown over time on a loglog plot. d, Plot of predicted concentration (𝑪(𝒕)) normalized to predicted concentration
maxima (𝑪𝒎𝒂𝒙) in the joints. 3-D stem plots show e, area under the concentration-time
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curve (𝑨𝑼𝑪𝟎
𝒌𝒐𝒖𝒕 (𝒉

𝟏

𝟐𝟒 𝒉 )

f, uptake rate constants, 𝒌𝒊𝒏 (𝒉

𝟏

), and g, elimination rate constants,

), for the joints in multiparameter space. Refer to Table S 2 for more details.
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Figure S 12: Kinetics of kidneys.
a, Observed concentration of kidneys normalized to concentration of heart (substitute for
plasma) is shown over time on a log-log plot. b, Plot of predicted concentration (𝑪(𝒕))
normalized to predicted concentration maxima (𝑪𝒎𝒂𝒙) in the kidneys. 3-D stem plots

show c, area under the concentration-time curve (𝑨𝑼𝑪𝟎
𝒌𝒊𝒏 (𝒉

𝟏

), and e, elimination rate constants, 𝒌𝒐𝒖𝒕 (𝒉

space. Refer to Table S 2 for more details.
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𝟏

𝟐𝟒 𝒉 ),

d, uptake rate constants,

), for the kidneys in multiparameter

Figure S 13: Functional relationships between MSN core size and area under the curve.
Linear and nonlinear functions were fit to obtain empirical relations for PEG-TMS coated
MSNs in different ROIs. Data represents mean ± SD, n = 4 (except TMS50 (i.p.) and
TMS25 (i.p.), where n = 3). Results of regression analysis including numerical coefficient
estimates, parameter P value, and coefficient of determination R2 are given in
corresponding tables. For the studies size range (32 – 142 nm), a consistent mathematical
relation between 𝑨𝑼𝑪𝟎
𝝀 ∙ 𝒔𝒊𝒛𝒆

𝟏

𝟐𝟒 𝒉

and particle core size was identified in the form of 𝑨𝑼𝑪𝟎

𝟐𝟒 𝒉

=

for all source-like organs for both i.v. and i.p.; however, for sink-like organs, two

such relations were identified, i.e., 𝑨𝑼𝑪𝟎

𝟐𝟒 𝒉

i.v. and i.p., respectively.
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= 𝝀 ∙ 𝒔𝒊𝒛𝒆 and 𝑨𝑼𝑪𝟎

𝟐𝟒 𝒉

= 𝝀 ∙ 𝒔𝒊𝒛𝒆𝟎.𝟓 , for

Figure S 14: PEG-TMS MSNs in urine.
Balb/C mice were injected with 1.5mg/mouse 50 nm PEG-TMS MSNs and urine was
collected 24 hours post injection. a,c,d TEM images of collected urine show the presence
of particles retaining the features of the original injected MSNs. Scale bar is 100 nm in a
and 50 nm in c and d. b, Spectral analysis confirmed the presence of silica in the particles
present in urine.
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Table S 1: Synthesis conditions of colloidally stable MSNs.
*TEOS:

tetraethyl

orthosilicate,

*

TMAC:

ammonium chloride
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N-trimethoxysilylpropyl-N,N,N-trimethyl

Table S 2: Non-linear regression analysis.
Values of model parameter estimates and coefficients of determination R2 are given for
various ROIs. P value for each parameter estimate is given in the corresponding
parenthesis. (Note: Abdominal aorta and lymph nodes were not analyzed as an ROI in the
i.p. and i.v. injection cases, respectively).
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Chapter 4 – Multiscale hybrid modeling approach
4.1. Introduction
Conventional chemotherapy continues to be the linchpin of clinical cancer intervention,
but is fraught with problems related to off-target cytotoxicity and drug resistance.
Nanoparticles (NPs) as drug delivery systems are a promising way to improve the narrow
therapeutic window196 of chemotherapeutics and overcome multidrug resistance197.
Leakiness of tumor vessels promotes NPs to accumulate in the tumor interstitium (referred
to as, enhanced permeability and retention (EPR) effect) 114,198, thus provides passive
targeting to the delivery of the cytotoxic cargo to the tumor. Further, by functionalizing the
surface of NPs with ligands specific to receptors in the tumor tissue (endothelium or
cancerous cell surface), NPs can be actively targeted164 to deliver the payload to the
tumor. Such strategies exploit the unique features of a tumor and ideally reduce the
delivery to non-target sites. NPs can also help the drug to circumvent mechanisms
responsible for drug resistance3 and act as a depot to maintain a therapeutic concentration
in biophase for a prolonged duration.
However, notwithstanding the promise, only moderate success has been achieved
in clinical translation of cancer nanotherapy1,138. As per a recent meta-analysis report139,
on an average only 0.7% of the injected dose of NPs is delivered to a tumor. In vivo
biodistribution studies26,199 have revealed preferential accumulation of NPs in
mononuclear phagocytic system (MPS) organs, like liver and spleen, thereby limiting the
bioavailability of NPs. Presence of Kupffer cells in liver, splenic macrophages, and
discontinuous endothelial capillaries (sinusoids) in liver and spleen create a
microenvironment that promotes NP accumulation in these organs53,187,200. Similarly, the
extent of presence of such microanatomical features in other organs governs the degree
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of accumulation of NPs in those organs, e.g. organs with fenestrated endothelial
capillaries189 (kidneys, pancreas) permit NP accumulation based on the relative size of
NPs and pores in such capillaries. However, in organs with continuous endothelial
capillaries189 (e.g., heart, lungs), NPs are beyond the filtration limit of the capillary wall,
hence negligible accumulation occurs. Thus, physiological features like pores and
macrophages, referred to here as traps, are the drivers of global NP biodistribution.
However, the effect of NP physicochemical properties, like size, charge, and surface
chemistry, cannot be ignored and it has been demonstrated that such properties play a
key role in tailoring NP biodistribution and clearance behavior 144,147,151,169,181. Hence, an
interplay between NP properties and anatomical features at the microscopic scale defines
the macroscopic behavior of NPs, and mathematical modeling approaches have been
applied to study such interactions.
By studying different scales in isolation, previous mathematical modeling works
have revealed valuable insights into the in vivo dynamics of NPs. Models at the cellular
scale41,59,201,202 have mechanistically explained NP-cellular interactions responsible for NP
phagocytosis, endothelial adhesion, vessel fenestration extravasation, and the effect of
NP physicochemical properties on such interactions. Computational fluid dynamic
simulations177,178,203 and models53,204-207 at the single capillary scale have provided
theoretical understanding of critical phenomenon like NP margination or lateral drift
towards vessel wall175, and effects of hematocrit, particle size, and shape on intravascular
behavior of NPs. Further, models at the tissue scale32,41,43,47,52,54 have studied the effects
of NP properties and tumor pathophysiology on the deliverability of NPs to the tumor.
Finally, whole-body physiologically based pharmacokinetic (PBPK) modeling 35-37
approaches have also been employed to understand global biodistribution behavior of
NPs. However, to our knowledge, modeling approaches that integrate multiple scales to

104

study tumor delivery of NPs are lacking. Since, NP-mediated drug delivery to tumors is a
multiscale process, a mathematical framework that integrates relevant scales can become
a powerful predictive tool to test in silico the effects of various particle-related and tissuerelated variables on the biological behavior of NPs and will allow to make suggestions for
NP design guidelines and physiological interventions. In this direction, we present an
integrative mathematical model that spans across multiple scales to study the delivery and
spatiotemporal distribution of NPs in a solid tumor.
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4.2. Methods
We base our model on the hypothesis that the organ-wise microvascular density of
physiological traps governs the global biodistribution of NPs, which is further fine-tuned by
NP physicochemical properties.
Model framework
The model is composed of three sub-models that operate at three different scales (see
Figure 4-1). The first sub-model is a simplistic physiologically based pharmacokinetic
(PBPK) model that operates at the whole-body scale and determines the temporal
evolution of systemic concentration of NPs. The systemic kinetics of NPs thus obtained
controls the rate of influx of NPs into the organ hosting the tumor. The second sub-model,
which acts at the tissue scale, focuses on the intravascular space of the microvasculature
of tumor. It simulates the trajectory of incoming NPs in the microvessels and predicts
delivery of NPs to tumorous tissue, by accounting for relevant microscopic traps
responsible for sequestration and removal of NPs from blood circulation. Whole-body
scale sub-model and tissue scale sub-model depend upon the third sub-model operating
at the cellular-scale to obtain a rate of trapping and probability of trapping, respectively,
determined through an analytical formulation. Thus, by integrating disposition kinetics of
NPs at the systemic circulation scale to NP-cellular interactions occurring at the cellular
scale, this multiscale in silico platform predicts the spatiotemporal evolution of NP
deposition in tumor microvasculature and extravasation into the tumor interstitium. As a
proof of principle, we focus on the human pancreas, hosting a confined pancreatic ductal
adenocarcinoma (resembling stage IA)208. The model has been developed completely in
MATLAB and has been parameterized with physiological values obtained through an inhouse histology study and published literature. We have not incorporated the
extravascular interstitial space into the current version of our model, but it is the logical
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Tissue scale

Whole-body scale

Systemic circulation

Rate of NP influx

Transport of NPs through
microvasculature of tumor tissue

Spatiotemporal evolution of NPs in
tumorous tissue

Liver, Kidneys

Trapping rate

Trapping probability

Cellular scale

Calculation of trapping rate
for each organ

Figure 4-1: Model overview.
A schematic of the multiscale nature of the model shows key components and system
interactions. The model is made up of three sub-models that operate at the whole-body
scale, tissue scale, and cellular scale. The whole-body scale model is a minimal PBPK
model that determines the systemic concentration-time profile of NPs, which serves as an
input for the tissue scale model in the form of rate of influx of NPs into the host organ and
tumor. In the tissue scale model, we simulate the transport of NPs through an abstractly
represented

intravascular

space

of

tumor

microvasculature,

and

predict

the

spatiotemporal evolution of sequestered NPs to study tumor delivery of nanomedicine.
Both the sub-models depend on the third sub-model operating at the cellular scale, which
determines the microscopic trapping rate for the PBPK model and trapping probability for
the tissue scale model.
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next step for a more comprehensive model to study cancer nanotherapy efficacy. We
now discuss the three sub-models in greater detail.

4.2.1

Whole-body scale sub-model

To estimate the macroscopic exposure of host organ and tumor to the injected NPs, we
use a reduced whole-body PBPK model9 and determine the systemic blood concentration
kinetics of NPs (see Figure 4-2). This reduction of the PBPK model is based on the
observation that renal and hepatic clearance are the primary drivers of systemic circulation
kinetics of NPs, thus our minimal PBPK model only includes systemic circulation, liver,
and kidney compartments. This sub-model is deterministic in nature and by applying mass
balance

to

each

compartment,

such

that

𝐹𝑟𝑒𝑒 𝑓𝑙𝑜𝑤𝑖𝑛𝑔 𝑁𝑃𝑠 = 𝐼𝑛𝑐𝑜𝑚𝑖𝑛𝑔 𝑁𝑃𝑠 −

𝑂𝑢𝑡𝑔𝑜𝑖𝑛𝑔 𝑁𝑃𝑠 − 𝑇𝑟𝑎𝑝𝑝𝑒𝑑 𝑁𝑃𝑠, we obtain the following coupled ordinary differential
equations (ODEs) for free-flowing NP concentration in different compartments shown in
Figure 4-2 (dotted red box):
Liver compartment
The liver has dual blood supply and is fed by the hepatic artery (300 𝑚𝑙𝑚𝑖𝑛

) and portal

vein. We do not explicitly model the organs feeding into portal vein (gut, spleen, and
pancreas). Given the high sequestration tendency of splenic tissue200 and low blood flow
rate of pancreas209, the contribution of spleen and pancreas for NPs into portal vein is
ignored. Thus, we only include the contribution of gut (1100 𝑚𝑙𝑚𝑖𝑛

) into the liver via

portal vein. We thus obtain:
= ((𝐶 − 𝐶 ) 𝑄

+𝑄

(1)

)/𝑉 − 𝐾 𝐶

where, 𝐶 and 𝐶 are the number concentrations (units, 𝑚𝑙
and systemic circulation, respectively. 𝑄

and 𝑄
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) of free-flowing NPs in liver

are the blood flow rates (units, 𝑚𝑙 ∙

𝑚𝑖𝑛

) of liver via hepatic artery and portal vein, respectively. 𝑉 is the volume of liver

(units, 𝑚𝑙), and 𝐾 is the trapping rate (units, 𝑚𝑖𝑛

) of NPs in liver (described in section

iii).
Kidney compartment
For renal clearance, we impose an upper bound of 6 nm,4 thus particles above 6 nm in
diameter will only be cleared by the liver53. Thus, for particles below 6 nm we obtain:
(2)

= (𝐶 − 𝐶 )𝑄 /𝑉 − 𝐾 𝐶
Where 𝐶 is the number concentration (units, 𝑚𝑙

) of free-flowing NPs in kidneys, 𝑉 is

the volume of kidneys, 𝐾 is the excretion rate of NPs from kidneys (value, 0.0013 𝑠

)4,

and 𝑄 is the blood flow rate of kidneys.
For particles above 6 nm, excretion rate will become zero and equation 2 is reduced to:
(3)

= (𝐶 − 𝐶 )𝑄 /𝑉
Systemic circulation compartment
= (𝐶 𝑄

+𝑄

+𝐶 𝑄 −𝐶 𝑄

+𝑄

+ 𝑄 )/𝑉

(4)

where 𝑉 is the volume of systemic blood pool.
Pancreas hosting tumor
We uncouple the pancreatic compartment from the above system of ODEs by not
incorporating the effect of pancreas into the portal vein, and thus obtain the following ODE
to obtain a solution for free-flowing NP concentration in pancreas (𝐶 (𝑡)). Since the host
organ is a source of blood-borne NPs for the tumor, this ODE also accounts for the NPs
supplied to the tumor.
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𝐶 (𝑡)

𝐶 (𝑡)

Systemic circulation

𝑄

+𝑄

(Hepatic artery + Portal vein)
Liver
𝑄

+𝑄

𝐾
Sequestration/Excretion

(Hepatic vein)

𝐶 (𝑡)
𝑄

(Renal artery)

𝐾
Kidneys

𝑄

Excretion

(Renal vein)
𝐶 (𝑡)

𝑄

(Pancreatic artery)

𝑄

(Pancreatic vein)

Pancreas
w/ tumor

Figure 4-2: Schematic of a minimal PBPK model.
A minimal PBPK model is employed to determine the systemic concentration time profile
of NPs to determine exposure of NPs to the host organ (pancreas) and tumor tissue. Our
simplistic PBPK model is driven by the assumption that liver and kidneys are the prime
determinants of systemic disposition kinetics of NPs. Mass balance employed to different
compartments accounts for incoming NPs, outgoing NPs, and trapped NPs, such that,
𝑭𝒓𝒆𝒆 𝒇𝒍𝒐𝒘𝒊𝒏𝒈 𝑵𝑷𝒔 = 𝑰𝒏𝒄𝒐𝒎𝒊𝒏𝒈 𝑵𝑷𝒔 − 𝑶𝒖𝒕𝒈𝒐𝒊𝒏𝒈 𝑵𝑷𝒔 − 𝑺𝒆𝒒𝒖𝒆𝒔𝒕𝒆𝒓𝒆𝒅 𝒐𝒓 𝑬𝒙𝒄𝒓𝒆𝒕𝒆𝒅 𝑵𝑷𝒔 .

Thus, the model includes four compartments (systemic circulation, liver, kidneys, and
pancreas) and is represented by three coupled ODEs and one uncoupled ODE. The
dotted line demarcates the coupled compartments of the model form the uncoupled
compartment.
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=

(5)

−𝐾 𝐶

where 𝑄 is the blood flow rate into pancreas, 𝑄 is the blood flow rate into tumor, 𝑉 is the
volume of pancreas, and 𝐾 is the trapping rate of NPs in healthy pancreatic tissue
(described in section iii).
We further obtain an ODE for the temporal evolution of concentration of free-flowing NPs
in the tumor:
=

(6)

−𝐾 𝐶

where 𝑉 is the volume of tumor and 𝐾 is the sequestration rate of NPs in the tumor
vasculature (described in section iii). The integral ∫ 𝐾 𝐶 𝑑𝑡 thus determines the exposure
of tumor tissue to drug-carrying NPs.

4.2.2

Tissue scale sub-model

As a proof of principle, we are simulating a clinically detectable primary pancreatic
ductal adenocarcinoma (PDA) (stage 1A)208,210. Instead of assuming the tumor to be a
three-dimensional compartment, we take a two-dimensional coarse-grained approach,
and model the intravascular space of the tumor in a semi-stochastic fashion. We assume
a non-growing circular tumor because the time scale of transport phenomenon for studying
pharmacokinetics of NPs is 24-72 hours compared to the much larger tumor volume
doubling time (e.g. for PDA is 144 days211). The components we incorporate into the 2-D
domain (see Figure 4-3) are the intravascular physiological traps that affect the residence
of NPs in microvasculature, namely, fenestrations, or inter-endothelial gaps, endothelium,
and macrophages. We use published and collected morphometric information to populate
the 2-D domain with traps (Table 2).
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a)

b)

Figure 4-3: Diagrammatic representation of a section of the tissue scale modeling domain.
a) Representation of a section of tissue perfused by a network of microvessels. The
components of interest are endothelial cells, macrophages, endothelial fenestrations or
inter-endothelial gaps, and nanoparticles flowing with blood in the vessels. Blood enters
the vascular network from the centrally located arteriolar opening and moves into the
capillary network, where the capillaries are lined by a single layer of endothelial cells, and
may have macrophages adhering to the vessel wall (particularly in mononuclear
phagocytic system organs, like, liver and spleen). Blood also brings with itself the injected
NPs (black dots). b) We abstractly model the tissue section by randomly, but uniformly,
distributing endothelial cells, pores, and macrophages in two-dimensional Euclidean
space of the same dimensions as that of the original tissue section. NPs originating from
the arteriolar opening move outwards in all directions according to a stochastic differential
equation leading to a biased random walk (pink trajectories), which represents motion of
NPs under the influence of pressure gradient-driven blood flow and inherent Brownian
motion.
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Table 2: List of model parameters and variables.
Value (References)

Parameter
Definition
Units
Whole-body scale parameters
𝑉
Volume of
𝑚𝑙
systemic
blood

5200212
Liver
(𝑖 = 𝑙)

𝑉

Volume
organ 𝑖

of

𝑄

Blood
flow
rate to organ
𝑖

𝑚𝑙

𝑚𝑙𝑚𝑖𝑛

1690(212)

300
(hepatic
artery)(21

Kidney
s (𝑖 =
𝑘)
280(212)

Pancrea
s (𝑖 = 𝑝)

Gut
(𝑖 = 𝑔)

Tumor
(𝑖 = 𝑡)

104(209)

-

1240(21

41(209)

1100
(feeds
into
portal
vein)(212

0.52
(based on
a tumor
dia. of 1
cm)
0.13(213)
(based on
a rate of
26
ml/min/10
0g&
assuming
a density
of 1g/ml)

2)

2)

)

Tissue scale parameters

𝜌

,

𝜌

,

𝜌

,

𝑑

,

𝜂

,

𝐿

number
density of
macrophage
s in organ
vasculature 𝑖
number
density of
endothelial
cells in organ
𝑖
number
density of
pores in
organ 𝑖
mean
diameter of
fenestrations
in organ 𝑖
rate of NP
extravasation
from pores in
organ 𝑖
length of a
capillary in
organ 𝑖

𝑚𝑚

Liver
(𝑖 = 𝑙)
485 (Fig. x)

Pancreas
(𝑖 = 𝑝)
-

Tumor
(𝑖 = 𝑡)
-

𝑚𝑚

785 (rat)(214)

1765 (Fig x)

1295 (perfused),
392 (seminecrotic)

𝑚𝑚

~107(215,216)

~107(217)

5*1295, 5*392
(hypothetical)

108(218)

60(217)

1000 (assumed)

0.5

0.5

0.5

1000

1000

𝑛𝑚

𝑠

𝜇𝑚
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𝑑

diameter of a
capillary in
organ 𝑖
drift velocity
of blood in
organ 𝑖
viscosity of
blood
Shear rate

,

𝜇

𝜂
𝑆
∆𝑃

𝑃

,

𝑃

,

𝑃

,

𝑃

,

𝑑

𝑝

𝜎

𝑑

𝜂

𝑘
𝑇

𝜇𝑚

𝜇𝑚𝑠

𝑐𝑃

6.5(215)

5 (assumed)

15(43,96)

4(219)

6(219)

calculated
4(219)

Pressure
gradient
across
capillary
Hydrostatic
pressure in
capillary
Hydrostatic
pressure in
interstitial
fluid

mmHg

Calculated using
equation
20(43)

mmHg

20(221)

20(221)

7.5(43)
(estimated)

mmHg

-3(221)

-3(221)

7.25(43)
(perfused),
7.475(43) (seminecrotic)

Osmotic
pressure in
capillary
Osmotic
pressure in
interstitial
fluid
Average
diameter of a
macrophage
power of
motor
proteins
surface
tension of
macrophage
membrane

mmHg

28(221)

28(221)

-

mmHg

8(221)

8(221)

-

Approximate
diameter of
an
endothelial
cell
rate of NP
internalizatio
n by
endothelial
cells
Boltzmann
constant
absolute
temperature

𝑠

75(220)
20(43)

7.543

𝜇𝑚

20(201)

𝑊

10-17 (201)

𝑁𝑚

6*10-5 (201)

50

𝜇𝑚

𝑠

calculated

𝐽𝐾

1.38*10-23
310

𝐾
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capillary wall
thickness
Simulation parameters
Time step of
𝛿𝑡
random walk
Variables
𝑑
diameter of
NP
Zeta
ζ
potential/char
ge of NP
∆𝑟

𝜇𝑚

0.0001 (Arbitrary)

𝑠

10-6

𝑛𝑚

20, 50, 100, 250

𝑚𝑉

-50, 0, 50
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Necrotic

Semi-necrotic

Well-perfused

Healthy

Arteriole
Pores
Endothelium
Fenestrations
Figure 4-4: Snapshot of simulation domain.
A snapshot of the simulation domain is shown. For computational efficiency, instead of
simulating the entire circular tumor, we only simulate a quadrant of the circle. The tumor
region is discretized into an outer well-perfused zone, middle semi-necrotic zone, and an
inner necrotic tumor core. Only for visual comparison, an outermost healthy tissue zone
is also shown in the snapshot, although it does not constitute a part of the simulated
domain.
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In the tumor, we impose intra-tumoral perfusion heterogeneity by discretizing the circular
tumor into three zones: (i) vascularized 𝟎. 𝟔𝑹𝒕 ≤ 𝒓 < 𝑹𝒕 (ii) semi-necrotic 𝟎. 𝟒𝑹𝒕 ≤ 𝒓 <
𝟎. 𝟔𝑹𝒕 , and (iii) necrotic 𝒓 ≤ 𝟎. 𝟏𝑹𝒕 , where 𝑹𝒕 is the radius of tumor222 (see

Figure 4-4). We do not include macrophages as traps in the tumor domain since
macrophages constitute a part of the interstitial space of the tumor.
Instead of modeling the bulk flow of NPs through intravascular space of healthy or
tumorous tissue, we focus on the motion of individual NPs using an agent-based
approach. Thus, we solve for the macroscopic convection-diffusion equation through
stochastic methods, namely, biased random-walk method that involves convective motion
of NPs in blood governed by a mean velocity vector, superimposed over diffusive
displacements sampled from a Gaussian distribution223. Stochastic solution of the
convection-diffusion equation is represented by an Itô stochastic differential equation
(SDE):
(7)

𝑑𝑋 = 𝜇𝑑𝑡 + √2𝐷𝑑𝑊

where 𝑋 is the nanovector jump length in time 𝑑𝑡; 𝜇 is the mean drift (or, velocity) vector
given by Eq. (7) (assumption: plug flow224,225); 𝐷 is the diffusion coefficient of nanovectors
determined by Eq. (8); and 𝑊 is the Wiener process.
To numerically solve Eq. (5), we used the Euler-Maruyama (EM) approximation
223,226

, which is the Markov chain given by:

𝑋

∆

(8)

= 𝑋 + 𝜇∆𝑡 + √2𝐷∆𝑊
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where the increment ∆𝑊 is a normally distributed random variable with mean 0 and
variance ∆𝑡.
Assuming blood to be a Newtonian fluid, and considering laminar flow, the average
drift vector 𝜇 is obtained through Hagen-Poiseuille equation given as:
(9)

𝜇 = ∆𝑃𝑟 /8𝜂𝐿

where ∆𝑃 is the pressure drop along a capillary of length 𝐿 and radius 𝑟 ; and 𝜂 is the
dynamic viscosity of blood. Diffusion coefficient 𝐷 for a spherical particle of radius 𝑟 is
obtained from the Stokes-Einstein equation, given as:
(10)

𝐷 = 𝑘 𝑇/6𝜋𝜂𝑟
where 𝑘 refers to Boltzmann’s constant; and 𝑇 is the absolute temperature.

4.2.3

Cellular scale sub-model

In order to solve the whole-body scale and tissue scale sub-models, we employ the cellular
scale model to estimate the trapping rate constant 𝐾 and trapping probability 𝑃 ,
respectively. This model accounts for nanoparticle margination 175 towards vessel wall, and
nanoparticle interaction with macrophages, endothelium, and pores or fenestrations in the
intravascular space of different tissues. The model is represented by the following
equation:
𝐾 = (𝑧 𝜌

,

𝜂 + 𝑧 𝜌 , 𝜂 + 𝑧 , 𝜌 , 𝜂 , )𝑉

(11)

,

Here, 𝑧 = 4𝜋𝑟 represents the surface area of effective trapping zone of a macrophage,
𝑧 = 𝜋𝑟 , and 𝑧

,

= 𝜋𝑟 , , are the areas of effective trapping zone of an endothelial cell

and a pore, respectively, where, 𝑟 , 𝑟 , and 𝑟
different organs. 𝜌

,

, 𝜌 , , and 𝜌

,

,

is their respective radius. 𝑟

,

can vary in

represent the number density of macrophages,
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endothelial cells, and pores, respectively in organ 𝑖. 𝜂 , 𝜂 , and 𝜂

,

represent the rate of

NP phagocytosis by macrophages, adhesion to endothelial cells, and extravasation from
pores, respectively (units, 𝑠
𝑉

,

).

represents dispersion factor or margination probability53,203 of NPs in microvasculature

of organ 𝑖 and is the ratio of rate of diffusion ( ) of NPs to their pressure gradient-driven
rate of convection ( ). Here, 𝐷 is the diffusion coefficient of NPs (units, μ𝑚 𝑠
from Stokes-Einstein equation (𝐷 =

) obtained

, where 𝑘 is the Boltzmann constant, 𝑇 is the

absolute temperature, and 𝜂 is the dynamic viscosity of blood). Dispersion factor quantifies
the lateral drift (margination) of NPs towards the vessel wall, allowing the particles to
encounter the traps.
𝜂 is the inverse of wrapping time that can be estimated by equating the mechanical work
performed by motor proteins for wrapping NPs against the elastic energy of the
macrophage membrane, from the following simplistic expression as derived by Lunov et
al.201:
𝜂

(12)

= 𝑝/𝜋𝑑 𝜎

where 𝑝 is the power of motor proteins, 𝑑 is the diameter of NPs, and 𝜎 is the surface
tension of the membrane.
To determine the rate of transvascular flux of NPs 𝜂

through vessel wall pores the

following model43,221 is used:
𝜂 = (𝑃(𝐶 − 𝐶 )

(13)

+ 𝐽 (1 − 𝜎)𝐶 )𝜋𝑟
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where

𝑃 – vascular permeability, 𝐶

- NP concentration in vasculature, 𝐶 - NP

concentration in interstitium, 𝑃 - Peclet number, 𝐽 - transvascular fluid flux, 𝜎 – vascular
reflection coefficient, 𝑟 - radius of pore
In order to obtain the rate of adhesion 𝜂 to endothelial cells, we use the expression
derived by Decuzzi et al.59 and adapted by Frieboes et al.54 to determine the strength and
likelihood of vascular adhesion of NPs.
(14)

𝜂 = 𝜂 𝛼𝑑 𝑒

where, 𝜂 - rate of NP flow, 𝛼, 𝛽, 𝛾 – NP-vascular affinity (density of surface receptors and
ligands, viscosity of medium), 𝑑 - diameter of NPs, 𝛿1, 𝛿2 - numerical coefficients, 𝑆- shear
rate.
Equations 12, 13, and 14 are divided by the rate of nanoparticle flow through a capillary
(𝜂 ) to obtain the probabilities of entrapment by macrophages, pores or fenestrations, and
endothelium respectively. The following equation estimates the upper bound on the rate
of flow of NPs through a capillary:
(15)

𝜂 = 𝐶 ∙𝑄

where, 𝐶 is systemic NP concentration 𝐶 at 𝑡 = 0 and is approximated by the ratio of
injected NPs 𝑁 and volume of systemic blood pool 𝑉 . 𝑄

is the blood flow rate inside

a capillary, given by:
𝑄

(16)

= 𝜇𝜋𝑟

Simulation algorithm
Our simulation algorithm (see Figure 4-5) simulates NP motion on a grid-free twodimensional space, consisting of a distribution of physiological traps, representing the
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intravascular space of tumorous tissue. We begin by initializing the 2-D domain with a
random uniform distribution of feeding arterioles and traps (Figure 4-4). SDE is solved by
the EM method for each NP appearing through one of the arteriolar sites, leading to a
random walk with a bias in the direction towards the core of the tumor, simulating NP
motion in blood inside a capillary arising from the arteriole. The maximum displacement
of a NP from the point of origin on the model domain is equal to ~tumor radius
(physiological value, Table 2). At every step within the allowed displacement, NPs are
tested for co-localization with a trap, which if determined positive is followed by testing for
margination, followed by testing for entrapment by endothelium or pores, governed by
their respective probabilities obtained from the cellular scale model. NPs that test positive
for both margination and entrapment cease to move forward, and their position and time
of capture by the trap is recorded to obtain spatiotemporal evolution. Computational
iterations continue for the sum of remaining particles and new incoming particles unless
the rate of influx of NPs from systemic circulation becomes zero.
Histology
In order to quantify the microvascular density of tumor tissue, human pancreatic ductal
adenocarcinoma specimens were labeled for CD34 (Figure 4-6a). Digital images of the
labeled specimens were then annotated by a pathologist to demarcate the tumor, tumorhealthy interface, and tumor regions of the specimens (see Figure 4-6b). The annotated
digital images were then processed using the Halo software to obtain area quantification
of positively and negatively stained regions in the three regions (see Figure 4-6c).

121

Start

Initialize spatial stochastic
component
Stop
Yes

Rate of NP
influx ≤ 0?

Book-keeping NP
position & timestamp
Yes

No

Margination,
Adhesion, &
Extravasation?

Initialize position of NPs
No
Solve SDE to update NP position

No

Move to next
time step

No

NP
displacement
≤ tumor
radius?

Yes

Figure 4-5: Simulation algorithm workflow of tissue scale model.
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Colocalization
of NPs
with traps?

Yes

Original

a)

Pathologist’s annotation

b)

Tumor
Healthy-tumor
interface
Healthy

Halo analysis

c)

Figure 4-6: Histological analysis.
CD34 immunohistochemistry was used to study vascular density in human pancreatic
specimens. a) Representative original images of tissue specimens at 1x, 3x, and 10x
magnifications. b) Images annotated by pathologist to demarcate healthy, healthy-tumor
interface, and tumorous regions. c) Images processed using Halo software to quantify
positively stained (brown) and negatively stained (green) regions.
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4.3. Results and Discussion
The model is aimed at testing the effect of NP physicochemical variables and physiological
interventions, like, vascular normalization, on tumor deployment efficiency of
nanomedicine. In this dissertation, we develop the model to obtain a baseline behavior.
Since the model is physiologically based, we obtain most of the parameter values from
published literature (Table 2). However, for vascular density we rely on an in-house
histological study. As seen in Figure 4-6, immunohistochemistry of human pancreatic
specimens for CD34 shows visual differences in the microvascular density between
healthy and tumor regions. Using pathologist-guided demarcations of different regions
(tumor, healthy, tumor-healthy interface) in individual specimens, analysis was performed
using Halo software to obtain quantitative differences in different regions. As seen in Figure
4-7, one-way ANOVA and Tukey’s test reveal higher vascular area density in healthy
pancreatic tissue over the interface and tumor regions. We translate vascular area density
into endothelial number density, by assuming a circular endothelial unit of radius 50 𝜇𝑚,
and thus dividing the total vascular area in the 2-D model domain by the area of unit
endothelium.
Using physiologically meaningful parameter values, we use the model to simulate
the injection of 10*109 NPs of size 25-nm, As seen in Figure 4-9, the whole-body scale
analytical model predicts the NP concentration kinetics in different compartments,
including free flowing NPs in systemic circulation, trapped NPs in liver, excreted NPs in
kidneys, and trapped NPs in tumor. Since particle size is above the cutoff for kidney
clearance, zero excretion through the renal route is predicted. In Figure 4-8. we also plot
predictions for the tumor from tissue scale numerical model (magenta dots). As seen,
there is a close resemblance between the predictions form the analytical model and
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Figure 4-7: Microvascular quantification.
Notched box plots showing vascular area quantification in healthy (N = 18), interface (N =
11), and tumor (N = 15) regions of human pancreatic specimens stained with anti-CD34
antibody (see Figure 4-6c). One-way ANOVA and Tukey’s test was performed on the
mean values to test for statistical significance. (*P < 0.05, ****P < 0.0001)
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Figure 4-8: Model predictions.
The predictions of concentration kinetics from the whole-body scale analytical model are
shown for free-flowing NPs in systemic blood pool, trapped NPs in liver, excreted NPs
from kidney, and trapped NPs in tumor. The predictions for tumor trapped NPs from the
tissue scale numerical model are superimposed on the same plot and we see a qualitative
consensus between analytical and numerical predictions.
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numerical model, giving a mathematical validation to our computational framework.
Since the analytical model does not provide any spatial information, we look at the
2-D tumor domain for spatial distribution of NPs and its change over time. As seen in
Figure 4-9, for a tumor with a diameter of 10 mm, the entrapment of NPs is more in the
outer well-perfused tumor region than the inner semi-necrotic domain. This can be
attributed to the greater trap density in outer region due to greater vascular density, i.e.
due to more vasculature, the number of vasculature associated traps increases, hence a
higher tendency of NPs to get trapped in the outer zone. As seen over time, the density of
trapped NPs continues to increase, with more particles in the outer region than inner.
There are no NPs entrapped in the necrotic tumor core due to absence of vasculature,
hence absence of traps. We further quantify the spatial distribution at the final time point
of simulation (1200 seconds), as seen in Figure 4-10, to obtain trapped fraction of NPs over
the radial distance form periphery of tumor to the core of the tumor. The trapped fraction
(ratio of trapped NPs over total NPs entered in tumor in 1200 seconds) decreases as we
more along the radius of the tumor form periphery to core.

4.4. Conclusions
Nanomedicine seems to bring us a step closer to Paul Ehrlich’s century-old idea of the
‘magic bullet’ for targeted chemotherapeutics227. However, due to challenges associated
with the accumulation of NPs in off-target sites, a multiscale approach needs to be
employed to understand the mechanisms of NP interactions with biological components
at the cellular scale leading to an emergent behavior at the macroscopic scale.
Mathematical modeling allows the integration of multiple scales to obtain an in-silico
platform capable of predicting the in vivo behavior of NPs under physiologically meaningful
conditions. This allows testing various NP-related physicochemical properties for their
effect on the biological behavior of NPs, and test physiological interventions that can
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120 sec

360 sec

Arteriole

Endothelium

Pores

Trapped NPs

1200 sec

Figure 4-9: Representative tissue scale model simulations.
Snapshots at 120 sec, 360 sec, and 1200 sec are shown for a simulation of nanoparticles
of size 25 nm. Over time, the number of trapped NPs in the tumor domain increases.
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Figure 4-10: Quantification of spatial distribution.
The entrapped NPs in the representative simulation of 25 nm sized NPs (Figure 4-9) are
quantified to obtain a spatial distribution of NPs along the radius of the tumor. Results
show a decline in the trapped fraction of NPs as we move from the periphery towards the
core of the tumor.
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improve the delivery of NPs to the targeted site.
In our multiscale modeling approach, we use NP interactions with cellular scale
components (endothelium, pores, macrophages) to determine the global biodistribution in
systemic circulation and other critical regions of interest. Where the analytical model
determines the temporal kinetics of NP concentration in different regions of interest, the
numerical model helps us understand the spatial distribution of NPs in the target site. We
recognize that the model is based on several justifiable simplifications and assumptions
and is only an abstract representation of the real system. However, given the complexity
of the multiscale system, it becomes important to do so.
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Chapter 5 – Conclusions and Future Directions
In this dissertation, we studied the problems and challenges associated with
nanomedicine using an integrative experimental and mathematical modeling approach.
We began with a comprehensive review of the literature to understand the various
mathematical modeling strategies employed to study biological behavior of nanoparticles.
We discussed models that operate at different scales, in particular, whole-body and tissue
scale.
Further, we demonstrated the application of a non-invasive SPECT/CT imaging
approach to perform pharmacokinetic analysis of nanoparticles, using MSNs as a
representative example. The range of the particles used to test the effect of size, charge,
and surface chemistry reveals that in vivo biodistribution and clearance of NPs is
significantly affected by these physiochemical properties. We justified the classification of
ROIs into source-like and sink-like organs based on their underlying physiological
differences and observed NP kinetics, and applied semi-mechanistic models to the
concentration-time profiles of NPs in these ROIs to determine relevant PK parameters.
Our analysis showed that smaller size corresponds with higher systemic bioavailability,
irrespective of route of delivery; positive charge favors greater excretion; and importantly
surface exposed charged molecules (amines) increase vulnerability to sequestration in
liver and spleen. Notably, a consistent mathematical relation between one key PK
parameter (𝐴𝑈𝐶

) and NP size was identified in the form of 𝐴𝑈𝐶

= 𝜆 ∙ 𝑠𝑖𝑧𝑒

for

systemic circulation and all source-like organs in both i.v. and i.p. cases; however, for sinklike organs, two such relations were identified, i.e., 𝐴𝑈𝐶
𝜆 ∙ 𝑠𝑖𝑧𝑒

.

, for i.v. and i.p. cases, respectively.
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= 𝜆 ∙ 𝑠𝑖𝑧𝑒 and 𝐴𝑈𝐶

=

Given the absence of multiscale mathematical models to study cancer
nanomedicine, we were motivated to develop a multiscale mechanistic model to study
nanomedicine delivery to a solid tumor. Our integrative model is composed of three submodels that operate at three different scales: whole-body, tissue, and cellular. The model
is parameterized with human physiological variables and can predict the spatiotemporal
distribution of NPs in a solid two-dimensional tumor. The model can be employed to study
the effect of NP physicochemical properties, e.g. size and surface chemistry, on the
deliverability of NPs to the tumor, under different pathophysiological conditions. For
instance, by varying the tumor vascular pore size and density, vascular normalization can
be simulated to study the effect of vascular normalization on improved tumor deliverability
of NPs of different size. Since the model is physiologically based, it can be employed to
all primary solid tumors and metastases by parameterizing the model with the values
specific to the given tumor-type.

In the current version of our cellular scale sub-model, we do not include the
effect of NP surface charge. However, we plan to improve the model further by
incorporating the effects of surface charge on transvascular flux, endocytosis, and
macrophage uptake in a future version. Also, we use ~6 nm as the size threshold
for renal clearance of NPs and based on empirical observations we use a constant
rate of renal clearance4. This can be further elaborated by incorporating
microscopic mechanisms like transcytosis to account for published observations 144
that involve renal clearance NPs larger than 6 nm. However, the time scale of such
microscopic mechanisms will govern the significance of such mechanisms in the
overall renal clearance of NPs. We also plan to validate the model by testing model
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predictions against published dynamic multidetector computed tomography data
for human pancreatic ductal adenocarcinoma228.
At the tissue scale, we do not account for interstitial tissue (extracellular
matrix and parenchyma) and can thus only predict tumor distribution of NPs based
on their intravascular behavior. However, in order to be able to predict therapy
efficacy, we will incorporate interstitial tissue in our 2D tumor domain.
At the whole-body scale, we only include the liver and kidney as the primary
drivers of systemic kinetics of NPs. However, we plan to further fine-tune the model
by extending he minimal PBPK model into a whole-body PBPK model and
incorporate the influence of other important organs.
Having established a physiologically based mechanistic model, we aim to
present a novel in silico platform that accounts for NP interactions with biological
components at the cellular scale and predicts the global biodistribution behavior of
NPs at the whole-body scale.
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Appendix A: Abbreviations
NP

nanoparticle

MSN

mesoporous silica nanoparticle

EPR

enhanced permeability and retention

MPS

mononuclear phagocytic system

PK

pharmacokinetics

PBPK

physiologically based pharmacokinetic

ODE

ordinary differential equation

PDE

partial differential equaiton

AUC

area under the curve

NCA

non-compartmental analysis

ECM

extracellular matrix

SPECT

single photon emission computed tomography

CT

computed tomography

PEG

polyethylene glycol

TMS

trimethylsilane

PEI

polyethyleneimine

QA

quaternary amine

TEM

transmission electron microscopy
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i.v.

intravenous

i.p.

intraperitoneal

ROI

region of interest

PdI

polydispersity index

DLS

dynamic light scattering

DTPA

diethylene triamine pentaacetic acid

p-SCN-Bn-DTPA

S-2-(4-Isothiocyanatobenzyl)-diethylenetriamine pentaacetic acid

APTES

3-aminopropyltriethoxysilane

TEOS

tetraethyl orthosilicate

NIBS

non-invasive backscatter optics
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Appendix B: Code
MATLAB code for chapter 4 can be found here:
https://drive.google.com/open?id=1rGSPX24Av6VM4wTDRjp-HC7-8Uv1qjgn
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